Phase 3 Readout Calendar
Industry-sponsored trials with primary completion in the next 12 months or last 12 months.
Data last updated September 20, 2026 · source: ClinicalTrials.gov
513
Next 6 months
889
Next 12 months
296
Results posted
748
Stale estimates
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 trial reading out in the next 12 months — searchable by sponsor, indication, or NCT, with a per-row staleness flag so you know which dates are still credible.
What's reading out at AstraZeneca in the next 6 months?
Filter by sponsor, then set the window to Next 6 months — it reveals a company's full near-term catalyst slate on one screen.
Which trials are completed but topline isn't out yet?
Filter confidence to “Completed · awaiting.” These are imminent or already-announced reads sitting in the FDAAA 12-month results-posting window.
Are there any GLP-1 or obesity Phase 3 readouts coming up?
Search “obesity” or “GLP-1” in the filter box, and combine with a sponsor such as Lilly or Novo Nordisk for tighter cuts.
Which sponsor-estimated dates haven't been updated in 12+ months?
Filter confidence to “Estimated · stale.” These are the dates most likely to slip — useful for watchlist hygiene and short-thesis scouting.
What's reading out in a specific quarter, like Q2 2026?
Use the window filter (Next 3 / 6 / 12 months) and combine with confidence to shortlist near-term, high-confidence catalysts.
Did a specific trial (NCT ID) read out yet?
Search by NCT ID. The confidence label tells you “Read out” (results posted) vs “Completed · awaiting” vs an estimated date.
Recently read-out results are free; the upcoming calendar shows a free preview, and filters are Pro. How we anchor dates & what we don't claim →
Browse by therapeutic area
Expected to have read out
· 230Industry Phase 3 trials whose estimated primary completion has passed in the last 3 months but CT.gov has not confirmed it — topline may be imminent, or the date may have slipped. Unconfirmed; most recently expected first.
Estimated completion has passed but CT.gov hasn't confirmed — topline may be imminent, or the date slipped · most recent: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (2026-09-18)
| Sponsor | Trial / Asset | Indication | Results | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Q3 2026 · 187 | ||||||
| Han Xu, M.D., Ph.D., FAPCR, Sponso… | Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms Asset: Topotecan - usual | SCLC | est. due Sep 2027 | Q3 2026 2026-09-18 (est.) | Estimated · aging
Updated 12mo ago
| NCT07145333 |
| Vertex Pharmaceuticals Incorporated | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant Asset: Biological/Vaccine | Type 1 Diabetes +1 | est. due Sep 2027 | Q3 2026 2026-09-17 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06832410 |
| Merck Sharp & Dohme LLC | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) Asset: Pembrolizumab | Endometrial Neoplasms | est. due Sep 2027 | Q3 2026 2026-09-15 (est.) | Estimated · stale
Updated 15mo ago
| NCT04634877 |
| Priovant Therapeutics, Inc. | A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis Asset: Brepocitinib PO QD | Uveitis, Posterior +2 | est. due Sep 2027 | Q3 2026 2026-09-11 (est.) | Estimated · aging
Updated 8mo ago
| NCT06431373 |
| Applied Biology, Inc. | Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia Asset: DA-007 | Chemotherapy Induced Alopecia +1 | est. due Sep 2027 | Q3 2026 2026-09-11 (est.) | Estimated · stale
Updated 16mo ago
| NCT06762548 |
| Galaxy Therapeutics INC | SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial | Intracranial Aneurysm | est. due Sep 2027 | Q3 2026 2026-09-10 (est.) | Estimated · aging
Updated 8mo ago
| NCT05831202 |
| GlaxoSmithKline | A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age Asset: Candidate varicella vaccine | Chickenpox | est. due Sep 2027 | Q3 2026 2026-09-10 (est.) | Estimated · aging
Updated 10mo ago
| NCT06855160 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia Asset: IBI306 | Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | est. due Sep 2027 | Q3 2026 2026-09-06 (est.) | Estimated · fresh
Updated 5mo ago
| NCT07473960 |
| H. Lundbeck A/S | A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine Asset: Eptinezumab | Chronic Migraine in Children | est. due Sep 2027 | Q3 2026 2026-09-05 (est.) | Estimated · fresh
Updated 6mo ago
| NCT04965675 |
| UCB BIOSCIENCES, Inc. | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome Asset: fenfluramine | Dravet Syndrome | est. due Sep 2027 | Q3 2026 2026-09-03 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06118255 |
| Boehringer Ingelheim | Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment Asset: zongertinib | Lung Cancer, Non-squamous, Non-small Cell | est. due Sep 2027 | Q3 2026 2026-09-02 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06151574 |
| Newron Pharmaceuticals SPA | Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia Asset: Evenamide 15 mg bid | Treatment-resistant Schizophrenia | est. due Sep 2027 | Q3 2026 2026-09-01 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07184619 |
| Incyte Corporation | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients Asset: Tafasitamab | Diffuse Large B-cell Lymphoma | est. due Sep 2027 | Q3 2026 2026-09-01 (est.) | Estimated · fresh
Updated 6mo ago
| NCT04824092 |
| Daewoong Pharmaceutical Co. LTD. | Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients Asset: DWP16001 Placebo | Type 2 Diabetic Nephropathy | est. due Sep 2027 | Q3 2026 2026-09-01 (est.) | Estimated · stale
Updated 24mo ago
| NCT06606093 |
| AbbVie | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab Asset: Adalimumab | Juvenile Psoriatic Arthritis | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT06100744 |
| Disc Medicine, Inc | Study of Bitopertin in Participants With EPP or XLP (APOLLO) Asset: Placebo | Erythropoietic Protoporphyria (EPP) +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06910358 |
| Clarity Pharmaceuticals Ltd | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy Asset: 64Cu-SAR-bisPSMA | Prostate Cancer +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06056830 |
| Alkermes, Inc. | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder Asset: OLZ/SAM | Schizophrenia +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT05303064 |
| TWi Biotechnology, Inc. | An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) Asset: AC-203 | Generalized Epidermolysis Bullosa Simplex | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06073132 |
| vTv Therapeutics | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Asset: Cadisegliatin 800 mg QD | Diabetes Mellitus, Type 1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06334133 |
| Jiangsu BioJeTay Biotechnology Co.… | Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients Asset: STSP-0601 for Injection | Hemophilia | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06922045 |
| Eli Lilly and Company | A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) Asset: LY3650150 | Perennial Allergic Rhinitis (PAR) | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06339008 |
| Curium US LLC | Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer Asset: Copper Cu 64 PSMA I&T | Prostate Cancer +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06235151 |
| argenx | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy Asset: Empasiprubart | Multifocal Motor Neuropathy (MMN) +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06742190 |
| Cook MyoSite | Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence Asset: AMDC-USR (iltamiocel) | Stress Urinary Incontinence | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · fresh
Updated 6mo ago
| NCT03104517 |
| Eli Lilly and Company | A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) Asset: Baricitinib | Systemic Juvenile Idiopathic Arthritis | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT04088396 |
| ScandiBio Therapeutics AB | Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease Asset: Combined metabolic activators | Alzheimer Disease | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT07062198 |
| Pharmazz, Inc. | Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke Asset: Drug: Normal Saline | Acute Ischemic Stroke +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 9mo ago
| NCT05691244 |
| Atea Pharmaceuticals, Inc. | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV Asset: Bemnifosbuvir-Ruzasvir (BEM/RZR) | HEPATITIS C VIRUS CHRONIC INFECTION | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 9mo ago
| NCT06868264 |
| Shandong Suncadia Medicine Co., Ltd. | A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy Asset: HRS-1893 Tablets | Obstructive Hypertrophic Cardiomyopathy | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 13mo ago
| NCT07021976 |
| EyeBiotech Ltd. | A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME Asset: Ranibizumab | Diabetic Macular Edema (DME) | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 13mo ago
| NCT06571045 |
| Qilu Pharmaceutical Co., Ltd. | GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer Asset: GM1 | Chemotherapy-induced Peripheral Neuropathy (CIPN) | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 13mo ago
| NCT06994507 |
| Intra-Cellular Therapies, Inc. | Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Asset: Lumateperone | Major Depressive Disorder | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 15mo ago
| NCT05850689 |
| Supernus Pharmaceuticals, Inc. | Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) Asset: SPN-812 | Attention-Deficit/Hyperactivity Disorder | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 15mo ago
| NCT02736656 |
| Mabwell (Shanghai) Bioscience Co.,… | A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer Asset: 9MW2821 | Advanced Urothelial Carcinoma | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 17mo ago
| NCT06196736 |
| Rophibio, Inc. | A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration Asset: RBS-001 Solution for intravitreal injection | Neovascular Age-related Macular Degeneration (nAMD) | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 17mo ago
| NCT06470373 |
| Bio-Thera Solutions | BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer Asset: Recombinant humanized anti-PD-1 monoclonal antibody injection | Cervical Cancer | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 19mo ago
| NCT06123884 |
| Alfasigma S.p.A. | Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis Asset: Filgotinib | Ulcerative Colitis | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 19mo ago
| NCT02914535 |
| Chia Tai Tianqing Pharmaceutical G… | A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients Asset: TQB2450+Anlotinib | Small Cell Lung Cancer Limited Stage | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 27mo ago
| NCT06469879 |
| Salutaris Medical Devices, Inc. | Adjunct Episcleral Brachytherapy for PCV Asset: Aflibercept Injection | Age-Related Macular Degeneration +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 37mo ago
| NCT05251636 |
| CSPC Zhongnuo Pharmaceutical (Shij… | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment Asset: Mitoxantrone hydrochloride liposome injection | Recurrent Metastatic Nasopharyngeal Carcinoma | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 43mo ago
| NCT05717764 |
| Daiichi Sankyo | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) Asset: Trastuzumab deruxtecan | Gastric Cancer, Adenocarcinoma +1 | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 8mo ago
| NCT04704934 |
| Hoffmann-La Roche | A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression Asset: Sefaxersen (RO7434656) | Primary IgA Nephropathy | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05797610 |
| Bayer | A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy Asset: BAY3723113 | Obstructive Hypertrophic Cardiomyopathy | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · fresh
Updated 5mo ago
| NCT07023341 |
| Pfizer | A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. Asset: RSVpreF | Respiratory Syncytial Virus (RSV) | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · fresh
Updated 5mo ago
| NCT07543380 |
| AMAG Pharmaceuticals, Inc. | A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) Asset: Ferumoxytol | Chronic Kidney Disease; Iron Deficiency Anemia | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · fresh
Updated 5mo ago
| NCT03619850 |
| Hansoh BioMedical R&D Company | Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure Asset: HS-20093 | Osteosarcoma | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06935409 |
| Anthos Therapeutics, Inc. | Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) Asset: Abelacimab | Atrial Fibrillation (AF) | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · fresh
Updated 6mo ago
| NCT05712200 |
| Sichuan Jishengtang Pharmaceutical… | Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney) Asset: Wujia Yizhi granules | Alzheimer's Dementia | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 9mo ago
| NCT06534723 |
| Kringle Pharma, Inc. | Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar Asset: KP-100LI | Vocal Fold Scar | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 9mo ago
| NCT05627648 |
| Daewon Pharmaceutical Co., Ltd. | Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma Asset: Experimental | Perennial Allergic Rhinitis Accompanied by Asthma | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 12mo ago
| NCT07168473 |
| Galderma R&D | Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Asset: Nemolizumab | Moderate-to-Severe Atopic Dermatitis | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · stale
Updated 23mo ago
| NCT03989206 |
| Pfizer | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Asset: Elranatamab | Multiple Myeloma | est. due Aug 2027 | Q3 2026 2026-08-30 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06152575 |
| Takeda | A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults Asset: Tetravalent Dengue Vaccine (TDV) | Dengue Fever | est. due Aug 2027 | Q3 2026 2026-08-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT07047521 |
| Keymed Biosciences Co.Ltd | Study of CM310 in Adolescent Subjects With Atopic Dermatis Asset: CM310 | Atopic Dermatitis | est. due Aug 2027 | Q3 2026 2026-08-30 (est.) | Estimated · aging
Updated 12mo ago
| NCT06495229 |
| Hutchmed | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Asset: Savolitinib | Non-small Cell Lung Cancer | est. due Aug 2027 | Q3 2026 2026-08-30 (est.) | Estimated · stale
Updated 13mo ago
| NCT05009836 |
| Beletalent (Zhuhai) Pharmaceutical… | Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy Asset: TNTL | Non-Proliferative Diabetic Retinopathy | est. due Aug 2027 | Q3 2026 2026-08-30 (est.) | Estimated · stale
Updated 13mo ago
| NCT06817265 |
| Il-Yang Pharm. Co., Ltd. | Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer Asset: Ilaprazole | Peptic Ulcer | est. due Aug 2027 | Q3 2026 2026-08-30 (est.) | Estimated · stale
Updated 16mo ago
| NCT06284876 |
| Panbela Therapeutics, Inc. | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer Asset: SBP-101 | Pancreatic Cancer Metastatic +2 | est. due Aug 2027 | Q3 2026 2026-08-29 (est.) | Estimated · stale
Updated 22mo ago
| NCT05254171 |
| Novartis Pharmaceuticals | Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer Asset: JDQ443 | Non-Small Cell Lung Cancer | est. due Aug 2027 | Q3 2026 2026-08-25 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05132075 |
| UCB Biopharma SRL | A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Asset: Brivaracetam | Childhood Absence Epilepsy +1 | est. due Aug 2027 | Q3 2026 2026-08-24 (est.) | Estimated · fresh
Updated 6mo ago
| NCT04666610 |
| AstraZeneca | A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease Asset: AZD9833 | ER-Positive HER2-Negative Breast Cancer | est. due Aug 2027 | Q3 2026 2026-08-24 (est.) | Estimated · aging
Updated 11mo ago
| NCT04711252 |
| Longboard Pharmaceuticals | A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) Asset: LP352 | Dravet Syndrome | est. due Aug 2027 | Q3 2026 2026-08-21 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06660394 |
| EMD Serono Research & Development … | Avelumab Program Rollover Study Asset: Avelumab | Solid Tumors | est. due Aug 2027 | Q3 2026 2026-08-21 (est.) | Estimated · fresh
Updated 6mo ago
| NCT03815643 |
| ViiV Healthcare | A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 Asset: CAB LA + RPV LA | HIV Infections | est. due Aug 2027 | Q3 2026 2026-08-19 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06694805 |
| Amgen | A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity Asset: Dazodalibep | Sjogren's Syndrome | est. due Aug 2027 | Q3 2026 2026-08-19 (est.) | Estimated · aging
Updated 8mo ago
| NCT06104124 |
| Merck Sharp & Dohme LLC | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) Asset: pembrolizumab/vibostolimab | Carcinoma, Non-Small-Cell Lung | est. due Aug 2027 | Q3 2026 2026-08-19 (est.) | Estimated · stale
Updated 14mo ago
| NCT05298423 |
| Shanghai Fudan-Zhangjiang Bio-Phar… | FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer Asset: FDA018-ADC | Triple Negative Breast Cancer | est. due Aug 2027 | Q3 2026 2026-08-18 (est.) | Estimated · aging
Updated 8mo ago
| NCT06519370 |
| Genzyme, a Sanofi Company | Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B Asset: Fitusiran | Hemophilia | est. due Aug 2027 | Q3 2026 2026-08-15 (est.) | Estimated · stale
Updated 13mo ago
| NCT03974113 |
| AstraZeneca | Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. Asset: Nexium 20mg | Erosive Esophagitis | est. due Aug 2027 | Q3 2026 2026-08-14 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05267613 |
| Incyte Corporation | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo Asset: Ruxolitinib Cream | NonSegmental Vitiligo | est. due Aug 2027 | Q3 2026 2026-08-10 (est.) | Estimated · aging
Updated 9mo ago
| NCT06548360 |
| Sanofi | A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population Asset: Yellow fever vaccine (live) | Yellow Fever Immunization | est. due Aug 2027 | Q3 2026 2026-08-08 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07103148 |
| UCB Biopharma SRL | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis Asset: Bimekizumab | Axial Spondyloarthritis +3 | est. due Aug 2027 | Q3 2026 2026-08-07 (est.) | Estimated · fresh
Updated 5mo ago
| NCT04436640 |
| Gan & Lee Pharmaceuticals. | A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise Asset: GZR18 | Type 2 Diabetes Mellitus (T2DM) | est. due Aug 2027 | Q3 2026 2026-08-07 (est.) | Estimated · aging
Updated 10mo ago
| NCT06777238 |
| Amgen | A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis Asset: Apremilast | Plaque Psoriasis | est. due Aug 2027 | Q3 2026 2026-08-06 (est.) | Estimated · aging
Updated 10mo ago
| NCT06088199 |
| Daiichi Sankyo | A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) Asset: T-DXd | Advanced Cancer +1 | est. due Aug 2027 | Q3 2026 2026-08-03 (est.) | Estimated · aging
Updated 11mo ago
| NCT06174987 |
| Sinovac (Dalian) Vaccine Technolog… | Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Asset: Varicella Vaccine | Varicella (Chickenpox) +1 | est. due Aug 2027 | Q3 2026 2026-08-01 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07473427 |
| Merck Sharp & Dohme LLC | A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) Asset: Tulisokibart | Ulcerative Colitis | est. due Aug 2027 | Q3 2026 2026-08-01 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06052059 |
| Innovent Biologics (Suzhou) Co. Ltd. | Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity Asset: IBI362 | Overweight +2 | est. due Aug 2027 | Q3 2026 2026-08-01 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07469800 |
| BioMarin Pharmaceutical | Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia Asset: Vosoritide | Hypochondroplasia | est. due Aug 2027 | Q3 2026 2026-08-01 (est.) | Estimated · aging
Updated 8mo ago
| NCT06455059 |
| Gan & Lee Pharmaceuticals. | A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM) Asset: GZR4 | Diabetes | est. due Aug 2027 | Q3 2026 2026-08-01 (est.) | Estimated · aging
Updated 10mo ago
| NCT06767735 |
| Jiangxi Kvvit Pharmaceutical Co., … | A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension Asset: Suraxavir Marboxil | Influenza | est. due Aug 2027 | Q3 2026 2026-08-01 (est.) | Estimated · stale
Updated 13mo ago
| NCT07113392 |
| AbbVie | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab Asset: Upadacitinib 15mg Dose | Atopic Dermatitis | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06389136 |
| Cybin IRL Limited | "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" Asset: CYB003 | Major Depressive Disorder | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06564818 |
| EyePoint Pharmaceuticals, Inc. | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 Asset: EYP-1901 | Wet Age Related Macular Degeneration +1 | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06668064 |
| AbbVie | ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars | Atrophic Acne Scars | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · stale
Updated 15mo ago
| NCT05995340 |
| Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK Asset: Tarcocimab tedromer | Wet Age-related Macular Degeneration | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 11mo ago
| NCT06556368 |
| Karyopharm Therapeutics Inc | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma Asset: Selinexor | Endometrial Cancer | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05611931 |
| Cerevance | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications Asset: CVN424 75 mg | Parkinson Disease | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06553027 |
| Eli Lilly and Company | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) Asset: Retatrutide | Diabetes Mellitus, Type 2 | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06260722 |
| Kedrion S.p.A. | A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) Asset: Kedrion IVIG 10% | Chronic Primary Immune Thrombocytopenia (ITP) | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07059000 |
| Grifols Therapeutics LLC | Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) Asset: Alpha-1 MP | Pulmonary Emphysema in Alpha-1 PI Deficiency | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 7mo ago
| NCT01983241 |
| Mirum Pharmaceuticals, Inc. | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) Asset: Brelovitug 300 mg | Chronic Hepatitis D Infection | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 7mo ago
| NCT07298330 |
| Akebia Therapeutics | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis Asset: Erythropoiesis-Stimulating Agent (ESA) | Anemia of Chronic Kidney Disease | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 7mo ago
| NCT06901505 |
| Pharvaris Netherlands B.V. | Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Asset: Deucrictibant | Hereditary Angioedema (HAE) | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 7mo ago
| NCT06669754 |
| HALEON | Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice Asset: Stannous fluoride and Potassium nitrate Dentifrice | Dentin Hypersensitivity | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 7mo ago
| NCT07215767 |
| Avidity Biosciences, Inc. | Global Study of Del-desiran for the Treatment of DM1 Asset: AOC 1001 (del-desiran) | DM1 +9 | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 8mo ago
| NCT06411288 |
| Ensysce Biosciences | PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) Asset: PF614 capsule | Postoperative Pain, Acute | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 8mo ago
| NCT06602271 |
| SK Life Science, Inc. | Cenobamate Open-Label Extension Study for YKP3089C025 Asset: Cenobamate | Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 8mo ago
| NCT03961568 |
| Pacira Pharmaceuticals, Inc | ZILRETTA in Subjects With Shoulder Osteoarthritis Asset: ZILRETTA | Glenohumeral Osteoarthritis | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 11mo ago
| NCT06269705 |
| Xenon Pharmaceuticals Inc. | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Asset: Azetukalner | Major Depressive Disorder | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 11mo ago
| NCT06775379 |
| Sol-Gel Technologies, Ltd. | Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Asset: Patidegib Topical Gel | Gorlin Syndrome | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 11mo ago
| NCT06050122 |
| Cinclus Pharma Holding AB | A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) Asset: Linaprazan glurate 50 mg Twice Daily (BID) | GERD (Gastroesophageal Reflux Disease) | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · aging
Updated 12mo ago
| NCT07037875 |
| AbbVie | A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants | Mid Face Volume Deficit | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · stale
Updated 13mo ago
| NCT07032597 |
| Pharmbio Korea Co., Ltd. | A Study to Evaluate Safety and Efficacy of PBK_M2502 Asset: PBK_M2502 1-Day | Intestinal Disease +3 | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · stale
Updated 13mo ago
| NCT07114406 |
| AbbVie | A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. Asset: Pomalidomide | Multiple Myeloma | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · stale
Updated 15mo ago
| NCT03539744 |
| Sunshine Lake Pharma Co., Ltd. | Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer Asset: Lerotinib | Esophageal Cancer | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · stale
Updated 16mo ago
| NCT04415853 |
| iVascular S.L.U. | Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy Asset: 1-month DAPT | Coronary Artery Disease | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · stale
Updated 16mo ago
| NCT05952206 |
| Shanghai Mabgeek Biotech.Co.Ltd | Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis Asset: Placebo | Prurigo Nodularis | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · stale
Updated 17mo ago
| NCT06779136 |
| CELL Technologies Inc. | Bone Marrow Aspirate Concentrate (BMAC) Treatment for Knee Osteoarthritis Asset: Autologous Bone Marrow Aspirate Concentrate | Knee Osteoarthritis +1 | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · stale
Updated 28mo ago
| NCT06216028 |
| Yantai LNC Biotechnology Singapore… | Clinical Study of 18F-Alfatide Injection PET/CT Asset: 18F-Alfatide Injection | Non-Small Cell Lung Cancer NSCLC | est. due Aug 2027 | Q3 2026 2026-08 (est.) | Estimated · stale
Updated 28mo ago
| NCT06416852 |
| Merck Sharp & Dohme LLC | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) Asset: Pembrolizumab | High-risk Non-muscle Invasive Bladder Cancer | est. due Jul 2027 | Q3 2026 2026-07-31 (est.) | Estimated · aging
Updated 9mo ago
| NCT03711032 |
| Jazz Pharmaceuticals | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Asset: Zanidatamab | Gastric Neoplasms +2 | est. due Jul 2027 | Q3 2026 2026-07-31 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05152147 |
| Alexion Pharmaceuticals, Inc. | A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH Asset: Danicopan | Paroxysmal Nocturnal Hemoglobinuria | est. due Jul 2027 | Q3 2026 2026-07-31 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05389449 |
| BioNTech SE | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age Asset: BNT162b2 Vaccine | COVID-19 +1 | est. due Jul 2027 | Q3 2026 2026-07-31 (est.) | Estimated · fresh
Updated 5mo ago
| NCT07300839 |
| Minghui Pharmaceutical (Hangzhou) … | MHB018A Treatment in Patients With Active Thyroid Eye Disease Asset: MHB018A | Thyroid Associated Ophthalmopathies | est. due Jul 2027 | Q3 2026 2026-07-31 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06989918 |
| Cerus Corporation | INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections | Anemia | est. due Jul 2027 | Q3 2026 2026-07-31 (est.) | Estimated · fresh
Updated 6mo ago
| NCT03037164 |
| Biogen | A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) Asset: Nusinersen | Muscular Atrophy, Spinal | est. due Jul 2027 | Q3 2026 2026-07-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT04729907 |
| BioNTech SE | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 Asset: BNT162b2 (2025/2026 formulation) | COVID-19 +1 | est. due Jul 2027 | Q3 2026 2026-07-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT07222384 |
| Jiangsu HengRui Medicine Co., Ltd. | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation Asset: Camrelizumab | Hepatocellular Carcinoma (HCC) | est. due Jul 2027 | Q3 2026 2026-07-31 (est.) | Estimated · aging
Updated 9mo ago
| NCT04639180 |
| MAXVAX Biotechnology Limited Liabi… | Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell) Asset: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) | Respiratory Syncytial Virus (RSV) | est. due Jul 2027 | Q3 2026 2026-07-31 (est.) | Estimated · aging
Updated 9mo ago
| NCT07272434 |
| BrightGene Bio-Medical Technology … | A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia Asset: BGM0504 | Type 2 Diabetes (T2DM) | est. due Jul 2027 | Q3 2026 2026-07-31 (est.) | Estimated · aging
Updated 11mo ago
| NCT07064486 |
| SK Plasma Co., Ltd. | An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients Asset: SKP-0141 | Hemophilia A, Severe | est. due Jul 2027 | Q3 2026 2026-07-31 (est.) | Estimated · stale
Updated 21mo ago
| NCT06738901 |
| Innervate Radiopharmaceuticals LLC… | Open-Label Study of 18F-mFBG for Imaging Neuroblastoma Asset: 18F-MFBG | Neuroblastoma | est. due Jul 2027 | Q3 2026 2026-07-30 (est.) | Estimated · fresh
Updated 6mo ago
| NCT04724369 |
| Jiangsu HengRui Medicine Co., Ltd. | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma Asset: TACE+Camrelizumab+Apatinib mesylate | Hepatocellular Carcinoma | est. due Jul 2027 | Q3 2026 2026-07-30 (est.) | Estimated · aging
Updated 9mo ago
| NCT05320692 |
| CSPC Megalith Biopharmaceutical Co… | Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） Asset: SYS6010 | EGFR-mutated Locally Advanced or Metastatic NSCLC | est. due Jul 2027 | Q3 2026 2026-07-30 (est.) | Estimated · aging
Updated 10mo ago
| NCT06927986 |
| ModernaTX, Inc. | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults Asset: mRNA-1345 | Respiratory Syncytial Virus | est. due Jul 2027 | Q3 2026 2026-07-30 (est.) | Estimated · stale
Updated 13mo ago
| NCT06067230 |
| Quoin Pharmaceuticals | Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome Asset: QRX003, 4% Lotion | Netherton Syndrome | est. due Jul 2027 | Q3 2026 2026-07-30 (est.) | Estimated · stale
Updated 14mo ago
| NCT06953466 |
| Pfizer | EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease Asset: nirmatrelvir | COVID-19 | est. due Jul 2027 | Q3 2026 2026-07-30 (est.) | Estimated · stale
Updated 14mo ago
| NCT05261139 |
| Shenyang Sunshine Pharmaceutical C… | SSGJ-707 in Advanced Non-Small Cell Lung Cancer Asset: SSGJ-707 | Advanced Non-Small Cell Lung Cancer | est. due Jul 2027 | Q3 2026 2026-07-30 (est.) | Estimated · stale
Updated 15mo ago
| NCT06980272 |
| Keymed Biosciences Co.Ltd | Study on the Treatment of Prurigo Nodularis With Stapokibart Injection Asset: Stapokibart | Prurigo Nodularis | est. due Jul 2027 | Q3 2026 2026-07-30 (est.) | Estimated · stale
Updated 16mo ago
| NCT06424470 |
| UCB Biopharma SRL | A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Asset: Bimekizumab | Hidradenitis Suppurativa | est. due Jul 2027 | Q3 2026 2026-07-28 (est.) | Estimated · fresh
Updated 5mo ago
| NCT04901195 |
| AstraZeneca | D9319C00001- 1L OC Mono Global RCT Asset: Olaparib | Ovarian Cancer | est. due Jul 2027 | Q3 2026 2026-07-27 (est.) | Estimated · aging
Updated 7mo ago
| NCT04884360 |
| Novavax | A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine Asset: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant | COVID-19 | est. due Jul 2027 | Q3 2026 2026-07-26 (est.) | Estimated · stale
Updated 14mo ago
| NCT06291857 |
| Bristol-Myers Squibb | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Asset: BMS-986165 | Psoriasis | est. due Jul 2027 | Q3 2026 2026-07-25 (est.) | Estimated · aging
Updated 11mo ago
| NCT04036435 |
| Shanghai Vitalgen BioPharma Co., L… | A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency | Aromatic L-amino Acid Decarboxylase Deficiency | est. due Jul 2027 | Q3 2026 2026-07-23 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06432140 |
| BioNTech SE | A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children Asset: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose | SARS-CoV-2 Virus +2 | est. due Jul 2027 | Q3 2026 2026-07-23 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05543616 |
| Chiesi Farmaceutici S.p.A. | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL Asset: metreleptin | Partial Lipodystrophy | est. due Jul 2027 | Q3 2026 2026-07-21 (est.) | Estimated · stale
Updated 13mo ago
| NCT05164341 |
| Bristol-Myers Squibb | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) Asset: Mezigdomide | Relapsed or Refractory Multiple Myeloma | est. due Jul 2027 | Q3 2026 2026-07-18 (est.) | Estimated · fresh
Updated 6mo ago
| NCT05552976 |
| GlaxoSmithKline | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease Asset: RSVPreF3 OA vaccine | Respiratory Syncytial Virus Infections | est. due Jul 2027 | Q3 2026 2026-07-16 (est.) | Estimated · fresh
Updated 5mo ago
| NCT07220109 |
| Alexion Pharmaceuticals, Inc. | Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis Asset: Ravulizumab | Generalized Myasthenia Gravis +1 | est. due Jul 2027 | Q3 2026 2026-07-15 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05644561 |
| Sinovac (Dalian) Vaccine Technolog… | Second Dose of Varicella Vaccine in Healthy Children Asset: PROVARIX | Varicella (Chickenpox) +1 | est. due Jul 2027 | Q3 2026 2026-07-15 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07475000 |
| Price Vision Group | Corneal Crosslinking for Treatment of Corneal Neovascularization | Corneal Neovascularization | est. due Jul 2027 | Q3 2026 2026-07-15 (est.) | Estimated · stale
Updated 14mo ago
| NCT04787471 |
| AstraZeneca | Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis Asset: Tezepelumab | Eosinophilic Esophagitis | est. due Jul 2027 | Q3 2026 2026-07-14 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05583227 |
| Regeneron Pharmaceuticals | A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) Asset: mibavademab | Generalized Lipodystrophy | est. due Jul 2027 | Q3 2026 2026-07-14 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06548100 |
| Pfizer | A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). Asset: PF-06821497 | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | est. due Jul 2027 | Q3 2026 2026-07-13 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06551324 |
| Incyte Corporation | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis Asset: Ruxolitinib | Atopic Dermatitis | est. due Jul 2027 | Q3 2026 2026-07-13 (est.) | Estimated · aging
Updated 9mo ago
| NCT06832618 |
| Novartis Pharmaceuticals | Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy Asset: Iptacopan | Atypical Hemolytic Uremic Syndrome | est. due Jul 2027 | Q3 2026 2026-07-09 (est.) | Estimated · fresh
Updated 6mo ago
| NCT04889430 |
| Bristol-Myers Squibb | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Asset: Nivolumab | Hepatocellular Carcinoma | est. due Jul 2027 | Q3 2026 2026-07-09 (est.) | Estimated · fresh
Updated 5mo ago
| NCT04039607 |
| Pharming Technologies B.V. | Pediatric Patients Aged 1 to 6 Years With APDS Asset: Leniolisib | APDS | est. due Jul 2027 | Q3 2026 2026-07-09 (est.) | Estimated · aging
Updated 11mo ago
| NCT05693129 |
| AstraZeneca | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) Asset: Trastuzumab deruxtecan | Breast Cancer; HER2-positive; Metastatic | est. due Jul 2027 | Q3 2026 2026-07-06 (est.) | Estimated · aging
Updated 7mo ago
| NCT04784715 |
| Merck Sharp & Dohme LLC | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Asset: Pembrolizumab | Lung Neoplasms +1 | est. due Jul 2027 | Q3 2026 2026-07-06 (est.) | Estimated · stale
Updated 13mo ago
| NCT04380636 |
| Qlaris Bio, Inc. | Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension Asset: Latanoprost (0.005%) | OAG - Open-Angle Glaucoma +1 | est. due Jul 2027 | Q3 2026 2026-07-01 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07354516 |
| Rapa Therapeutics LLC | RAPA-501 Therapy for ALS Asset: RAPA-501 Autologous T stem cells | Amyotrophic Lateral Sclerosis | est. due Jul 2027 | Q3 2026 2026-07-01 (est.) | Estimated · stale
Updated 15mo ago
| NCT04220190 |
| GlaxoSmithKline | A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age Asset: Investigational varicella vaccine | Chickenpox | est. due Jul 2027 | Q3 2026 2026-07-01 (est.) | Estimated · stale
Updated 20mo ago
| NCT06693895 |
| Shanghai JMT-Bio Inc. | Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer Asset: JMT101 | Squamous Cell Non-small Cell Lung Cancer | est. due Jul 2027 | Q3 2026 2026-07-01 (est.) | Estimated · stale
Updated 30mo ago
| NCT06319313 |
| Samson Clinical Operations Pty Ltd | Efficacy & Safety of Minoxidil SL Tablets in Men With AGA Asset: Minoxidil | Androgenetic Alopecia +1 | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 14mo ago
| NCT06924632 |
| Praxis Precision Medicines | A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine Asset: 1.0mg/kg/day PRAX-562 | Developmental and Epileptic Encephalopathy 1 | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 9mo ago
| NCT07010471 |
| Sichuan Kelun-Biotech Biopharmaceu… | A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer Asset: SKB264 | Triple Negative Breast Cancer | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 8mo ago
| NCT06279364 |
| BeOne Medicines | Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies Asset: Tislelizumab | Advanced Malignancies | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · fresh
Updated 5mo ago
| NCT04164199 |
| Ultragenyx Pharmaceutical Inc | Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) Asset: GTX-102 | Angelman Syndrome | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 7mo ago
| NCT06617429 |
| AMAG Pharmaceuticals, Inc. | A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects Asset: ferumoxytol | Iron Deficiency Anemia | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · fresh
Updated 5mo ago
| NCT03893045 |
| Colgate Palmolive | Efficacy of a Toothpaste in Reducing Plaque, Gingivitis, and Gingival Bleeding Asset: Toothpaste containing chitosan | Plaque, Dental +1 | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · fresh
Updated 5mo ago
| NCT07499115 |
| pH-D Feminine Health LLC | Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis Asset: Boric acid | Vulvovaginal Candidiases +2 | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07109869 |
| Italfarmaco | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera Asset: Givinostat | Polycythemia Vera | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06093672 |
| Harmony Biosciences Management, Inc. | A Study of Pitolisant in Patients With Prader-Willi Syndrome Asset: Pitolisant tablet | Prader-Willi Syndrome | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06366464 |
| Sarfez Pharmaceuticals, Inc. | A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease Asset: Combination Product: FDC of spironolactone and ER torsemide | Hypertension (HTN) | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07223502 |
| Lexicon Pharmaceuticals | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy Asset: Sotagliflozin | Obstructive Cardiomyopathy, Hypertrophic +1 | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 7mo ago
| NCT06481891 |
| Curadel Surgical Innovations, Inc. | Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery Asset: Nizaracianine Triflutate | Injury of Ureter During Surgery (Disorder) | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 7mo ago
| NCT06101745 |
| Viridian Therapeutics, Inc. | A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) Asset: VRDN-003 | Thyroid Eye Disease | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 8mo ago
| NCT07155668 |
| AbbVie | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis Asset: Upadacitinib | Rheumatoid Arthritis | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 8mo ago
| NCT05814627 |
| Qilu Pharmaceutical Co., Ltd. | QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia Asset: QL0911 | Cancer Treatment-Induced Thrombocytopenia | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 8mo ago
| NCT06456528 |
| Staidson (Beijing) Biopharmaceutic… | To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome Asset: STSA-1002 injection | Acute Respiratory Distress Syndrome (ARDS) | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 9mo ago
| NCT07208591 |
| ALK-Abelló A/S | A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65 Asset: HDM SLIT-tablet (12 SQ-HDM) | Allergic Rhinoconjunctivitis +1 | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 9mo ago
| NCT07060885 |
| EMS | Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus Asset: MADALENA ASSOCIATION | Type 2 Diabetes Mellitus | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 9mo ago
| NCT04670666 |
| EMS | Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus Asset: PIEMONTE | Type II Diabetes | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 9mo ago
| NCT05028140 |
| Camurus AB | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET Asset: CAM2029 | Gastro-enteropancreatic Neuroendocrine Tumor | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 10mo ago
| NCT05050942 |
| HUYABIO International, LLC. | Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma Asset: HBI-8000 in combination with nivolumab | Unresectable or Metastatic Melanoma +1 | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · aging
Updated 12mo ago
| NCT04674683 |
| AbbVie | Long-term Safety and Efficacy Extension Trial of Bimatoprost SR Asset: Bimatoprost SR | Open-Angle Glaucoma +1 | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 13mo ago
| NCT03891446 |
| Shanghai Hengrui Pharmaceutical Co… | A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma Asset: SHR-A2102 for Injection | Advanced Urothelial Carcinoma | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 14mo ago
| NCT06738251 |
| Sichuan Baili Pharmaceutical Co., … | A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Asset: SI-B001 | Non-small Cell Lung Adenocarcinoma +1 | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 15mo ago
| NCT05943795 |
| InnoPharmax Inc. | Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer Asset: D07001-softgel capsules + Xeloda (or TS-1) | Biliary Tract Cancer | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 17mo ago
| NCT05065957 |
| Suzhou Suncadia Biopharmaceuticals… | The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis Asset: SHR-1314 | Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 19mo ago
| NCT06833307 |
| Qilu Pharmaceutical Co., Ltd. | Study on the Efficacy and Safety of QLM1016 in Schizophrenia Asset: 3-6mg QLM1016 | Schizophrenia | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 20mo ago
| NCT06799559 |
| SUNHO（China）BioPharmaceutical CO.,… | To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer Asset: IAH0968 | Stomach Neoplasms +1 | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 20mo ago
| NCT06504732 |
| Chia Tai Tianqing Pharmaceutical G… | A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects Asset: TQF3510 (Semaglutide Injection) | Obesity | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 21mo ago
| NCT06738979 |
| Infan Industria Quimica Farmaceuti… | EFFICACY OF ORAL AROEIRA (Schinus Terebinthifolia Raddi) COMPARED TO OMEPRAZOLE IN DYSPEPPSIA Asset: Oral Aroeira | Dyspepsia | est. due Jul 2027 | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 29mo ago
| NCT04069286 |
| Q2 2026 · 43 | ||||||
| Johnson & Johnson Enterprise Innov… | JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC Asset: JNJ-90301900 (NBTXR3) | Carcinoma, Squamous Cell | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · fresh
Updated 6mo ago
| NCT04892173 |
| Aragon Pharmaceuticals, Inc. | An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Asset: Apalutamide | Prostatic Neoplasms | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · fresh
Updated 5mo ago
| NCT02531516 |
| Novartis Pharmaceuticals | Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD Asset: Pelacarsen | Cardiovascular Disease and Lipoprotein(a) | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · fresh
Updated 6mo ago
| NCT04023552 |
| Visirna Therapeutics HK Limited | A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients Asset: VSA003 | Homozygous Familial Hypercholesterolemia (HoFH) | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 22mo ago
| NCT06712771 |
| Shanghai Jiaolian Drug Research an… | A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. Asset: B007 | Generalized Myasthenia Gravis | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 23mo ago
| NCT06447597 |
| PTC Therapeutics | A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria Asset: PTC923 | Phenylketonuria | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05166161 |
| Taizhou Hanzhong biomedical co. LTD | A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer Asset: HX008(Pucotenlimab) | Metastatic Colorectal Cancer | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05652894 |
| Seagen, a wholly owned subsidiary … | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Asset: disitamab vedotin | Urothelial Carcinoma | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05911295 |
| Beacon Therapeutics | A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP Asset: rAAV2tYF-GRK1-hRPGRco | X-Linked Retinitis Pigmentosa | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · fresh
Updated 5mo ago
| NCT04850118 |
| Astellas Pharma Global Development… | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy Asset: Fezolinetant | Hot Flashes | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06440967 |
| Olema Pharmaceuticals, Inc. | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Asset: Palazestrant | Breast Cancer +4 | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06016738 |
| KalVista Pharmaceuticals, Ltd. | An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) Asset: KVD900 600 mg | Hereditary Angioedema | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT05505916 |
| Hoffmann-La Roche | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab Asset: Atezolizumab | Unresectable Hepatocellular Carcinoma | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT04770896 |
| Celcuity Inc | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) Asset: Gedatolisib | Breast Cancer | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT05501886 |
| AstraZeneca | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer Asset: Durvalumab | Non-Small Cell Lung Cancer | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · aging
Updated 8mo ago
| NCT05221840 |
| Shanghai Henlius Biotech | A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer Asset: HLX10 | Limited-Stage Small Cell Lung Cancer | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · aging
Updated 8mo ago
| NCT05353257 |
| Laboratorios Sophia S.A de C.V. | PRO-232 in Patients Subjected to Cataract Surgery Asset: Moxifloxacin / Dexamethasone Ophthalmic Solution | Cataract Extraction | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · aging
Updated 9mo ago
| NCT07305987 |
| Kexing Biopharm Co., Ltd. | Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy Asset: PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.) | Neutropenia, Chemotherapy-Induced Febrile +1 | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · aging
Updated 10mo ago
| NCT06711523 |
| Sunshine Guojian Pharmaceutical (S… | Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis Asset: 611 | Dermatitis, Atopic | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · aging
Updated 10mo ago
| NCT07042126 |
| MicuRx | Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI) Asset: contezolid acefosamil (IV)/contezolid (PO) | Diabetic Foot Infection | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · aging
Updated 12mo ago
| NCT05369052 |
| Onconic Therapeutics Inc. | Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease Asset: JP-1366 + placebo | Non-erosive Gastroesophageal Reflux Disease | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · aging
Updated 12mo ago
| NCT07160790 |
| Prime Gene Therapeutics Co., Ltd. | A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis Asset: PG-011 nasal spray 0.6%(twice daily) | Seasonal Allergic Rhinitis +1 | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 13mo ago
| NCT07146126 |
| KalVista Pharmaceuticals, Ltd. | PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial Asset: KVD900 600 mg | Hereditary Angioedema | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 14mo ago
| NCT05511922 |
| GC Biopharma Corp | A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. Asset: Undiluted I.V.-Hepabig inj(GC5103) | Hepatitis B | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 15mo ago
| NCT05686759 |
| Zenas BioPharma (USA), LLC | A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) Asset: Obexelimab | Warm Autoimmune Hemolytic Anemia | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 15mo ago
| NCT05786573 |
| Apnimed | Continuation Protocol for Obstructive Sleep Apnea (OSA) Asset: Aroxybutynin and Atomoxetine | OSA | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 16mo ago
| NCT06566820 |
| CSPC ZhongQi Pharmaceutical Techno… | The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression Asset: Ammoxetine | Major Depressive Disorder (MDD) | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 19mo ago
| NCT06827431 |
| Telix Pharmaceuticals (Innovations… | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study Asset: 89Zr-TLX250 PET/CT | Clear Cell Renal Cell Carcinoma | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 21mo ago
| NCT06750419 |
| PharmaEssentia Japan K.K. | Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients Asset: P1101 (Ropeginterferon alfa-2b) | Polycythemia Vera (PV) | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 22mo ago
| NCT04655092 |
| Il-Yang Pharm. Co., Ltd. | A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs Asset: Radotinib HCl | Chronic Myeloid Leukemia, Chronic Phase +3 | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 23mo ago
| NCT03459534 |
| Tego Science, Inc. | A Phase 2b/3 Study of TPX-115 on Partial-thickness Rotator Cuff Tear Asset: TPX-115 | Partial Thickness Rotator Cuff Tear | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 27mo ago
| NCT06414005 |
| Kexing Biopharm Co., Ltd. | Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections Asset: Human interferon α1b Inhalation Solution | Respiratory Syncytial Virus Infections | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 29mo ago
| NCT06363370 |
| Beijing Union Pharmaceutical Facto… | Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD Asset: Buagafuran capsules, 15mg/ capsule | Generalized Anxiety Disorder | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 31mo ago
| NCT06243640 |
| Beijing Union Pharmaceutical Facto… | Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD Asset: Buagafuran capsules, 15mg/ capsule | Generalized Anxiety Disorder | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 31mo ago
| NCT06243614 |
| United BioPharma | UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection Asset: UB-421 | HIV-1 Infection | est. due Jun 2027 | Q2 2026 2026-06-30 (est.) | Estimated · stale
Updated 41mo ago
| NCT04406727 |
| Sanofi | A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis Asset: Amlitelimab | Dermatitis Atopic | est. due Jun 2027 | Q2 2026 2026-06-29 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06407934 |
| Novo Nordisk A/S | A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes Asset: Oral semaglutide | Type 2 Diabetes | est. due Jun 2027 | Q2 2026 2026-06-29 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07271251 |
| EMS | Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea Asset: CDE100 association | Primary Dysmenorrhea | est. due Jun 2027 | Q2 2026 2026-06-28 (est.) | Estimated · aging
Updated 9mo ago
| NCT05640232 |
| Albireo, an Ipsen Company | Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD) Asset: Odevixibat | Biliary Atresia | est. due Jun 2027 | Q2 2026 2026-06-26 (est.) | Estimated · fresh
Updated 6mo ago
| NCT04336722 |
| Ipsen | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. Asset: Elafibranor | Primary Biliary Cholangitis | est. due Jun 2027 | Q2 2026 2026-06-26 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06383403 |
| Janssen Research & Development, LLC | A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis Asset: Nipocalimab | Myasthenia Gravis | est. due Jun 2027 | Q2 2026 2026-06-26 (est.) | Estimated · fresh
Updated 6mo ago
| NCT05265273 |
| Guangdong Hengrui Pharmaceutical C… | Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis Asset: SHR-1819 Injection | Prurigo Nodularis | est. due Jun 2027 | Q2 2026 2026-06-25 (est.) | Estimated · stale
Updated 23mo ago
| NCT06554509 |
| Alebund Pharmaceuticals | A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China Asset: AP301 | Hyperphosphatemia +3 | est. due Jun 2027 | Q2 2026 2026-06-20 (est.) | Estimated · aging
Updated 8mo ago
| NCT06933472 |
Recently read out & awaiting topline
· 245Phase 3 trials whose primary completion is CONFIRMED by CT.gov (last 12 months) — results posted, or completed and awaiting topline. Most recent first.
All 245 completed and awaiting topline — CT.gov results typically post within 12 months of completion · most recent confirmed: Inventera Inc. (2026-04-14)
| Sponsor | Trial / Asset | Indication | Results | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Q2 2026 · 7 | ||||||
| Inventera Inc. | Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint Diseases Asset: NEMO-103 Injection | Rotator Cuff Tear +7 | Due Apr 2027 | Q2 2026 2026-04-14 | Completed · awaiting
Updated 5mo ago
| NCT07057037 |
| UCB Biopharma SRL | A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis Asset: Certolizumab pegol | Moderate Chronic Plaque Psoriasis +2 | Due Apr 2027 | Q2 2026 2026-04-09 | Completed · awaiting
Updated 5mo ago
| NCT04123795 |
| Alcon Research | Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction | Ocular Hypertension +1 | Due Apr 2027 | Q2 2026 2026-04-06 | Completed · awaiting
Updated 5mo ago
| NCT07082816 |
| Arog Pharmaceuticals, Inc. | Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Asset: Crenolanib | Newly Diagnosed FLT3 Mutated AML | Due Apr 2027 | Q2 2026 2026-04-06 | Completed · awaiting
Updated 5mo ago
| NCT03258931 |
| Ondine Biomedical Inc. | Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections | Surgical Site Infections +3 | Due Apr 2027 | Q2 2026 2026-04-03 | Completed · awaiting
Updated 5mo ago
| NCT06702878 |
| Arog Pharmaceuticals, Inc. | Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML Asset: Crenolanib | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | Due Apr 2027 | Q2 2026 2026-04-03 | Completed · awaiting
Updated 5mo ago
| NCT03250338 |
| Insmed Incorporated | An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Pulmonary Hypertension +1 | Due Apr 2027 | Q2 2026 2026-04-01 | Completed · awaiting
Updated 5mo ago
| NCT05649722 |
| Q1 2026 · 83 | ||||||
| Novartis Pharmaceuticals | Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Asset: Fingolimod | Multiple Sclerosis (MS) | Due Mar 2027 | Q1 2026 2026-03-25 | Completed · awaiting
Updated 6mo ago
| NCT04926818 |
| Novartis Pharmaceuticals | Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD Asset: Pelacarsen | Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease | Due Mar 2027 | Q1 2026 2026-03-25 | Completed · awaiting
Updated 5mo ago
| NCT06267560 |
| Astellas Pharma Inc | A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause Asset: Fezolinetant | Hot Flashes | Due Mar 2027 | Q1 2026 2026-03-19 | Completed · awaiting
Updated 5mo ago
| NCT06206421 |
| Incyte Corporation | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) Asset: Povorcitinib | NonSegmental Vitiligo | Due Mar 2027 | Q1 2026 2026-03-17 | Completed · awaiting
Updated 6mo ago
| NCT06113471 |
| Eli Lilly and Company | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk Asset: Orforglipron | Type 2 Diabetes +5 | Due Mar 2027 | Q1 2026 2026-03-16 | Completed · awaiting
Updated 5mo ago
| NCT05803421 |
| Sandoz | A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Asset: GME751 | Metastatic NSCLC | Due Mar 2027 | Q1 2026 2026-03-16 | Completed · awaiting
Updated 5mo ago
| NCT06159790 |
| Regeneron Pharmaceuticals | Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma Asset: Fianlimab | Melanoma | Due Mar 2027 | Q1 2026 2026-03-12 | Completed · awaiting
Updated 5mo ago
| NCT05352672 |
| Merck Sharp & Dohme LLC | A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | Lung Cancer +1 | Due Mar 2027 | Q1 2026 2026-03-12 | Completed · awaiting
Updated 6mo ago
| NCT06698042 |
| argenx | A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). Asset: efgartigimod | Primary Immune Thrombocytopenia | Due Mar 2027 | Q1 2026 2026-03-11 | Completed · awaiting
Updated 6mo ago
| NCT04225156 |
| Amgen | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer Asset: Romiplostim | Chemotherapy-induced Thrombocytopenia | Due Mar 2027 | Q1 2026 2026-03-10 | Completed · awaiting
Updated 5mo ago
| NCT03937154 |
| AstraZeneca | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Asset: Placebo | Chronic Obstructive Pulmonary Disease (COPD) | Due Mar 2027 | Q1 2026 2026-03-06 | Completed · awaiting
Updated 6mo ago
| NCT06040086 |
| Novo Nordisk A/S | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Asset: Cagrilintide | Type 2 Diabetes | Due Mar 2027 | Q1 2026 2026-03-04 | Completed · awaiting
Updated 5mo ago
| NCT06221969 |
| Eli Lilly and Company | A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Asset: Mirikizumab | Ulcerative Colitis | Due Mar 2027 | Q1 2026 2026-03-04 | Completed · awaiting
Updated 5mo ago
| NCT03519945 |
| Sanofi | Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa Asset: avalglucosidase alfa | Glycogen Storage Disease Type II | Due Mar 2027 | Q1 2026 2026-03-02 | Completed · awaiting
Updated 5mo ago
| NCT04910776 |
| Sarfez Pharmaceuticals, Inc. | Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone | Bioavailability Heathy Volunteers | Due Feb 2027 | Q1 2026 2026-02-28 | Completed · awaiting
Updated 6mo ago
| NCT07046975 |
| AstraZeneca | Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). | Chronic Obstructive Pulmonary Disease (COPD) | Due Feb 2027 | Q1 2026 2026-02-26 | Completed · awaiting
Updated 6mo ago
| NCT05742802 |
| Incyte Corporation | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) Asset: Povorcitinib | NonSegmental Vitiligo | Due Feb 2027 | Q1 2026 2026-02-24 | Completed · awaiting
Updated 6mo ago
| NCT06113445 |
| Novartis Pharmaceuticals | Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission Asset: Secukinumab 300 mg, s.c. | Giant Cell Arteritis | Due Feb 2027 | Q1 2026 2026-02-24 | Completed · awaiting
Updated 7mo ago
| NCT05380453 |
| AstraZeneca | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC Asset: Tremelimumab | Hepatocellular Carcinoma | Due Feb 2027 | Q1 2026 2026-02-23 | Completed · awaiting
Updated 5mo ago
| NCT05301842 |
| Karyopharm Therapeutics Inc | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Asset: Selinexor | Myelofibrosis | Due Feb 2027 | Q1 2026 2026-02-20 | Completed · awaiting
Updated 5mo ago
| NCT04562389 |
| Novartis Pharmaceuticals | A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia Asset: Ianalumab | Warm Autoimmune Hemolytic Anemia (wAIHA) | Due Feb 2027 | Q1 2026 2026-02-20 | Completed · awaiting
Updated 6mo ago
| NCT05648968 |
| Pfizer | Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Asset: talazoparib plus enzalutamide | Prostate Cancer | Due Feb 2027 | Q1 2026 2026-02-18 | Completed · awaiting
Updated 5mo ago
| NCT04821622 |
| Celltrion | A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis Asset: CT-P55 | Plaque Psoriasis | Due Feb 2027 | Q1 2026 2026-02-18 | Completed · awaiting
Updated 7mo ago
| NCT06630559 |
| Bristol-Myers Squibb | A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Asset: Nivolumab | Urinary Bladder Neoplasms +1 | Due Feb 2027 | Q1 2026 2026-02-16 | Completed · awaiting
Updated 5mo ago
| NCT03661320 |
| RDC Clinical Pty Ltd | Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population Asset: Maolactin | Chronic Inflammation +3 | Due Feb 2027 | Q1 2026 2026-02-16 | Completed · awaiting
Updated 7mo ago
| NCT06444763 |
| Astellas Pharma Global Development… | A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity Asset: mirabegron | Neurogenic Detrusor Overactivity | Due Feb 2027 | Q1 2026 2026-02-16 | Completed · awaiting
Updated 7mo ago
| NCT05621616 |
| Beijing Suncadia Pharmaceuticals C… | A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty Asset: SHR-2004 injection | Prevention of Arterial and Venous Thrombosis | Due Feb 2027 | Q1 2026 2026-02-15 | Completed · awaiting
Updated 5mo ago
| NCT06825416 |
| Boston Scientific Corporation | MANDARIN (S6371) | Inoperable Hepatocellular Carcinoma | Due Feb 2027 | Q1 2026 2026-02-13 | Completed · awaiting
Updated 5mo ago
| NCT05016245 |
| Viridian Therapeutics, Inc. | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) Asset: VRDN-003 | Thyroid Eye Disease | Due Feb 2027 | Q1 2026 2026-02-12 | Completed · awaiting
Updated 5mo ago
| NCT06625411 |
| Taisho Pharmaceutical Indonesia | Counterpain PXM Versus Diclofenac Versus Piroxicam | Ankle Sprain +4 | Due Feb 2027 | Q1 2026 2026-02-12 | Completed · awaiting
Updated 6mo ago
| NCT07475663 |
| PTC Therapeutics | Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) Asset: Ataluren | Duchenne Muscular Dystrophy | Due Feb 2027 | Q1 2026 2026-02-10 | Completed · awaiting
Updated 6mo ago
| NCT01247207 |
| UCB Biopharma SRL | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis Asset: Bimekizumab | Psoriatic Arthritis | Due Feb 2027 | Q1 2026 2026-02-06 | Completed · awaiting
Updated 5mo ago
| NCT06624228 |
| Janssen Research & Development, LLC | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome Asset: Milvexian | Acute Coronary Syndrome | Due Feb 2027 | Q1 2026 2026-02-06 | Completed · awaiting
Updated 5mo ago
| NCT05754957 |
| Forma Therapeutics, Inc. | A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) Asset: Etavopivat Tablets Low dose | Sickle Cell Disease | Due Feb 2027 | Q1 2026 2026-02-06 | Completed · awaiting
Updated 5mo ago
| NCT04624659 |
| Daewoong Pharmaceutical Co. LTD. | A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension Asset: DWC202405 | Essential Hypertension | Due Feb 2027 | Q1 2026 2026-02-05 | Completed · awaiting
Updated 6mo ago
| NCT06671392 |
| Pfizer | A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo Asset: Ritlecitinib | Stable Nonsegmental Vitiligo +1 | Due Feb 2027 | Q1 2026 2026-02-05 | Completed · awaiting
Updated 7mo ago
| NCT05583526 |
| AbbVie | A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality | Skin Quality Deficit | Due Feb 2027 | Q1 2026 2026-02-05 | Completed · awaiting
Updated 7mo ago
| NCT06547125 |
| AbbVie | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma | Open-Angle Glaucoma | Due Feb 2027 | Q1 2026 2026-02-04 | Completed · awaiting
Updated 7mo ago
| NCT05411198 |
| CSPC Baike (Shandong) Biopharmaceu… | A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus Asset: TG103 | Type 2 Diabetes Mellitus | Due Feb 2027 | Q1 2026 2026-02-03 | Completed · awaiting
Updated 6mo ago
| NCT06235086 |
| Immunovant Sciences GmbH | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Asset: Batoclimab | Thyroid Eye Disease | Due Feb 2027 | Q1 2026 2026-02-03 | Completed · awaiting
Updated 6mo ago
| NCT05524571 |
| Merck Sharp & Dohme LLC | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) Asset: Belzutifan | Carcinoma, Renal Cell | Due Feb 2027 | Q1 2026 2026-02-02 | Completed · awaiting
Updated 7mo ago
| NCT04586231 |
| United Therapeutics | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Asset: Placebo | Idiopathic Pulmonary Fibrosis +1 | Due Feb 2027 | Q1 2026 2026-02-02 | Completed · awaiting
Updated 5mo ago
| NCT04708782 |
| Tasly Pharmaceutical Group Co., Ltd | A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis Asset: pimavanserin tartrate | Parkinson's Disease Psychosis | Due Feb 2027 | Q1 2026 2026-02-01 | Completed · awaiting
Updated 7mo ago
| NCT06068465 |
| Hoffmann-La Roche | A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) Asset: Giredestrant | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | Due Jan 2027 | Q1 2026 2026-01-30 | Completed · awaiting
Updated 7mo ago
| NCT04546009 |
| Mundipharma Research Limited | Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Asset: Rezafungin for Injection | Candidemia +9 | Due Jan 2027 | Q1 2026 2026-01-29 | Completed · awaiting
Updated 5mo ago
| NCT04368559 |
| Vertex Pharmaceuticals Incorporated | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older Asset: ELX/TEZ/IVA | Cystic Fibrosis | Due Jan 2027 | Q1 2026 2026-01-29 | Completed · awaiting
Updated 7mo ago
| NCT05153317 |
| Novartis Pharmaceuticals | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab Asset: Ofatumumab approved dose | Relapsing Multiple Sclerosis (RMS) | Due Jan 2027 | Q1 2026 2026-01-28 | Completed · awaiting
Updated 5mo ago
| NCT06869785 |
| Colgate Palmolive | The Efficacy of a Battery Toothbrush in the Reduction of Established Plaque and Gingivitis Asset: Total Active Prevention Fresh Toothpaste + Colgate Total Active Prevention Battery Toothbrush | Plaque +1 | Due Jan 2027 | Q1 2026 2026-01-28 | Completed · awaiting
Updated 7mo ago
| NCT07224828 |
| Hoffmann-La Roche | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) Asset: Fenebrutinib | Relapsing Multiple Sclerosis | Due Jan 2027 | Q1 2026 2026-01-27 | Completed · awaiting
Updated 7mo ago
| NCT04586010 |
| Cassiopea SpA | A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss Asset: Clascoterone 5% solution | Alopecia, Androgenetic | Due Jan 2027 | Q1 2026 2026-01-26 | Completed · awaiting
Updated 6mo ago
| NCT05910450 |
| CSPC Baike (Shandong) Biopharmaceu… | A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus Asset: TG103 | Type 2 Diabetes Mellitus | Due Jan 2027 | Q1 2026 2026-01-23 | Completed · awaiting
Updated 6mo ago
| NCT06258148 |
| Eli Lilly and Company | Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Asset: Retatrutide | Diabetes Type 2 | Due Jan 2027 | Q1 2026 2026-01-22 | Completed · awaiting
Updated 7mo ago
| NCT06354660 |
| AstraZeneca | A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). Asset: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate | Chronic Obstructive Pulmonary Disease | Due Jan 2027 | Q1 2026 2026-01-22 | Completed · awaiting
Updated 7mo ago
| NCT06067828 |
| Sun Pharmaceutical Industries Limi… | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. Asset: Tildrakizumab 100 mg | Moderate to Severe Genital Psoriasis | Due Jan 2027 | Q1 2026 2026-01-21 | Completed · awaiting
Updated 6mo ago
| NCT06611163 |
| Eli Lilly and Company | A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Asset: Tirzepatide | Overweight +1 | Due Jan 2027 | Q1 2026 2026-01-20 | Completed · awaiting
Updated 6mo ago
| NCT06047548 |
| Takeda | A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases Asset: TAK-881 | Primary Immunodeficiency Diseases (PID) | Due Jan 2027 | Q1 2026 2026-01-20 | Completed · awaiting
Updated 8mo ago
| NCT05755035 |
| Sanofi | Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults Asset: Yellow fever vaccine (live) | Yellow Fever Immunization | Due Jan 2027 | Q1 2026 2026-01-20 | Completed · awaiting
Updated 8mo ago
| NCT07002060 |
| IBSA Institut Biochimique SA | Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer. Asset: Progesterone-IBSA Injectable Solution | Infertility | Due Jan 2027 | Q1 2026 2026-01-20 | Completed · awaiting
Updated 8mo ago
| NCT04549116 |
| AstraZeneca | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Asset: Tozorakimab | Chronic Obstructive Pulmonary Disease (COPD) | Due Jan 2027 | Q1 2026 2026-01-19 | Completed · awaiting
Updated 5mo ago
| NCT05166889 |
| AstraZeneca | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. Asset: Tozorakimab | Chronic Obstructive Pulmonary Disease (COPD) | Due Jan 2027 | Q1 2026 2026-01-19 | Completed · awaiting
Updated 5mo ago
| NCT05158387 |
| Nanjing Zenshine Pharmaceuticals | Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza Asset: ZX-7101A for oral suspension | Respiratory Viral Infection | Due Jan 2027 | Q1 2026 2026-01-16 | Completed · awaiting
Updated 5mo ago
| NCT07095257 |
| Lipocine Inc. | A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD Asset: LPCN 1154A | Depression, Postpartum +5 | Due Jan 2027 | Q1 2026 2026-01-16 | Completed · awaiting
Updated 7mo ago
| NCT06979544 |
| Bristol-Myers Squibb | A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Asset: mavacamten | Hypertrophic Cardiomyopathy +2 | Due Jan 2027 | Q1 2026 2026-01-16 | Completed · awaiting
Updated 7mo ago
| NCT03723655 |
| Dizal Pharmaceuticals | A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) Asset: sunvozertinib | Non-small Cell Lung Cancer | Due Jan 2027 | Q1 2026 2026-01-16 | Completed · awaiting
Updated 7mo ago
| NCT05668988 |
| Yuhan Corporation | Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis Asset: YHP2401 | Acute Bronchitis | Due Jan 2027 | Q1 2026 2026-01-15 | Completed · awaiting
Updated 7mo ago
| NCT07111468 |
| Immedica Pharma AB | Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia Asset: Chronocort | Congenital Adrenal Hyperplasia | Due Jan 2027 | Q1 2026 2026-01-15 | Completed · awaiting
Updated 7mo ago
| NCT05299554 |
| KalVista Pharmaceuticals, Ltd. | Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II Asset: KVD900 150 mg | Hereditary Angioedema | Due Jan 2027 | Q1 2026 2026-01-15 | Completed · awaiting
Updated 8mo ago
| NCT06467084 |
| Shanghai Hutchison Pharmaceuticals… | Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy Asset: Shenqi Sherong Pill | Cervical Spondylotic Myelopathy | Due Jan 2027 | Q1 2026 2026-01-14 | Completed · awaiting
Updated 5mo ago
| NCT06377072 |
| Palvella Therapeutics, Inc. | SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations Asset: QTORIN 3.9% Rapamycin Anhydrous Gel | Microcystic Lymphatic Malformation | Due Jan 2027 | Q1 2026 2026-01-14 | Completed · awaiting
Updated 6mo ago
| NCT06239480 |
| Merck Sharp & Dohme LLC | Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) Asset: pembrolizumab | Hodgkin Lymphoma | Due Jan 2027 | Q1 2026 2026-01-14 | Completed · awaiting
Updated 7mo ago
| NCT02684292 |
| Amgen | A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease Asset: Teprotumumab | Thyroid Eye Disease | Due Jan 2027 | Q1 2026 2026-01-14 | Completed · awaiting
Updated 8mo ago
| NCT06248619 |
| Eli Lilly and Company | A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Asset: Lebrikizumab | Atopic Dermatitis +1 | Due Jan 2027 | Q1 2026 2026-01-14 | Completed · awaiting
Updated 8mo ago
| NCT05559359 |
| Seagen, a wholly owned subsidiary … | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Asset: Brentuximab vedotin | Diffuse Large B-cell Lymphoma | Due Jan 2027 | Q1 2026 2026-01-12 | Completed · awaiting
Updated 5mo ago
| NCT04404283 |
| Janssen Research & Development, LLC | A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis Asset: Ustekinumab | Arthritis, Juvenile | Due Jan 2027 | Q1 2026 2026-01-12 | Completed · awaiting
Updated 5mo ago
| NCT05083182 |
| Pfizer | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma Asset: Encorafenib | Melanoma | Due Jan 2027 | Q1 2026 2026-01-12 | Completed · awaiting
Updated 5mo ago
| NCT04657991 |
| Xenon Pharmaceuticals Inc. | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures Asset: XEN1101 | Focal Onset Seizures | Due Jan 2027 | Q1 2026 2026-01-12 | Completed · awaiting
Updated 6mo ago
| NCT05614063 |
| Eli Lilly and Company | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Asset: Selpercatinib | Carcinoma, Non-Small-Cell Lung | Due Jan 2027 | Q1 2026 2026-01-12 | Completed · awaiting
Updated 7mo ago
| NCT04819100 |
| Chiesi Farmaceutici S.p.A. | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD Asset: Beclomethasone Dipropionate | COPD +1 | Due Jan 2027 | Q1 2026 2026-01-12 | Completed · awaiting
Updated 8mo ago
| NCT04320342 |
| RDC Clinical Pty Ltd | LC-Plasma for Preventing URTIs and Reducing Symptoms | Healthy Volunteer +1 | Due Jan 2027 | Q1 2026 2026-01-10 | Completed · awaiting
Updated 7mo ago
| NCT06827327 |
| Eli Lilly and Company | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Asset: Ixekizumab | Psoriasis +1 | Due Jan 2027 | Q1 2026 2026-01-08 | Completed · awaiting
Updated 8mo ago
| NCT06588283 |
| Alexion Pharmaceuticals, Inc. | Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP Asset: ALXN1850 | Hypophosphatasia | Due Jan 2027 | Q1 2026 2026-01-06 | Completed · awaiting
Updated 7mo ago
| NCT06079359 |
| Chengdu Suncadia Medicine Co., Ltd. | Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment Asset: HRS-5965 capsule | Paroxysmal Nocturnal Hemoglobinuria | Due Jan 2027 | Q1 2026 2026-01-06 | Completed · awaiting
Updated 8mo ago
| NCT06715943 |
| Alexion Pharmaceuticals, Inc. | Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Asset: Ravulizumab | Immunoglobulin A Nephropathy +1 | Due Jan 2027 | Q1 2026 2026-01-05 | Completed · awaiting
Updated 5mo ago
| NCT06291376 |
| Q4 2025 · 137 | ||||||
| United Therapeutics | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients Asset: Ralinepag | PAH +10 | Due Dec 2026 | Q4 2025 2025-12-31 | Completed · awaiting
Updated 5mo ago
| NCT03626688 |
| Innovent Biologics (Suzhou) Co. Ltd. | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC Asset: IBI310 | Hepatocellular Carcinoma | Due Dec 2026 | Q4 2025 2025-12-31 | Completed · awaiting
Updated 6mo ago
| NCT04720716 |
| RDC Clinical Pty Ltd | Effectiveness of a Grape Seed Extract on Circulatory Measures in Healthy Adults Asset: Grape Seed Extract | Circulatory; Change | Due Dec 2026 | Q4 2025 2025-12-31 | Completed · awaiting
Updated 7mo ago
| NCT06440252 |
| Bayer | A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease Asset: Finerenone (BAY94-8862) | Non-diabetic Chronic Kidney Disease | Due Dec 2026 | Q4 2025 2025-12-31 | Completed · awaiting
Updated 7mo ago
| NCT05047263 |
| Hoffmann-La Roche | A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer Asset: Atezolizumab | Non-Small Cell Lung Cancer | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 6mo ago
| NCT05047250 |
| Colgate Palmolive | Clinical Investigation of PerioGard (Test) Regimen Asset: PeriGuard regimen | Gingivitis | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 6mo ago
| NCT07210138 |
| Quoin Pharmaceuticals | Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome Asset: QRX003-2% Lotion | Netherton Syndrome | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 6mo ago
| NCT05521438 |
| Sarfez Pharmaceuticals, Inc. | A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects | Bioavailability Heathy Volunteers | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 7mo ago
| NCT07043634 |
| Sarfez Pharmaceuticals, Inc. | Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects Asset: 10 mg Torsemide tablet | Bioequivalence Study in Healthy Subjects +1 | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 7mo ago
| NCT07015671 |
| Mineralys Therapeutics Inc. | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension Asset: Lorundrostat | Hypertension | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 7mo ago
| NCT05968430 |
| Hoffmann-La Roche | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer Asset: Atezolizumab | Non-Small Cell Lung Cancer | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 8mo ago
| NCT04294810 |
| Bayer | A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema Asset: 8 mg aflibercept (BAY 86-5321) (High Dose) | Diabetic Macular Edema | Due Dec 2026 | Q4 2025 2025-12-29 | Completed · awaiting
Updated 6mo ago
| NCT06422507 |
| Alexion Pharmaceuticals, Inc. | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG Asset: Eculizumab | Generalized Myasthenia Gravis (gMG) +1 | Due Dec 2026 | Q4 2025 2025-12-29 | Completed · awaiting
Updated 8mo ago
| NCT06764160 |
| Sanofi Pasteur, a Sanofi Company | Phase 3 Single Arm, Open Study on vYF in Adults Asset: Yellow fever vaccine (live) | Yellow Fever | Due Dec 2026 | Q4 2025 2025-12-25 | Completed · awaiting
Updated 8mo ago
| NCT07222059 |
| Haisco Pharmaceutical Group Co., L… | Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia Asset: HSK39297 tablets | Paroxysmal Nocturnal Haemoglobinuria (PNH) | Due Dec 2026 | Q4 2025 2025-12-23 | Completed · awaiting
Updated 7mo ago
| NCT07052838 |
| SynOx Therapeutics Limited | Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) Asset: Emactuzumab | TGCT | Due Dec 2026 | Q4 2025 2025-12-23 | Completed · awaiting
Updated 8mo ago
| NCT05417789 |
| Amzell | A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms Asset: AMZ001 Diclofenac gel | Osteoarthritis of Knee +1 | Due Dec 2026 | Q4 2025 2025-12-22 | Completed · awaiting
Updated 8mo ago
| NCT06693648 |
| Hoffmann-La Roche | A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy Asset: Obinutuzumab | Primary Membranous Nephropathy | Due Dec 2026 | Q4 2025 2025-12-22 | Completed · awaiting
Updated 5mo ago
| NCT04629248 |
| Rhythm Pharmaceuticals, Inc. | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway Asset: Setmelanotide | Obesity +1 | Due Dec 2026 | Q4 2025 2025-12-22 | Completed · awaiting
Updated 7mo ago
| NCT05093634 |
| Merck Sharp & Dohme LLC | V114 and Acute Otitis Media (V114-032/PNEU-ERA) Asset: V114 | Acute Otitis Media (AOM) | Due Dec 2026 | Q4 2025 2025-12-22 | Completed · awaiting
Updated 8mo ago
| NCT04193215 |
| Pfizer | Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Asset: Abrocitinib 100 mg | Dermatitis, Atopic | Due Dec 2026 | Q4 2025 2025-12-22 | Completed · awaiting
Updated 8mo ago
| NCT03422822 |
| Colgate Palmolive | Clinical Study to Evaluate the Tooth Whitening Efficacy of a New NextGen In-office Whitening System Asset: Beaming White | Health Adult Subjects | Due Dec 2026 | Q4 2025 2025-12-21 | Completed · awaiting
Updated 8mo ago
| NCT07225478 |
| Boston Scientific Corporation | A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort | In-Stent Restenosis | Due Dec 2026 | Q4 2025 2025-12-19 | Completed · awaiting
Updated 6mo ago
| NCT06492174 |
| QED Therapeutics, a BridgeBio comp… | A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia Asset: Infigratinib 0.25 mg/kg/day | Achondroplasia | Due Dec 2026 | Q4 2025 2025-12-18 | Completed · awaiting
Updated 6mo ago
| NCT06164951 |
| Quince Therapeutics S.p.A. | Evaluate the Neurological Effects of EryDex on Subjects With A-T | Ataxia Telangiectasia | Due Dec 2026 | Q4 2025 2025-12-17 | Completed · awaiting
Updated 8mo ago
| NCT06193200 |
| Sanofi | A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease Asset: Venglustat (GZ402671) | Fabry Disease | Due Dec 2026 | Q4 2025 2025-12-17 | Completed · awaiting
Updated 7mo ago
| NCT05206773 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight | Obesity +1 | Due Dec 2026 | Q4 2025 2025-12-12 | Completed · awaiting
Updated 5mo ago
| NCT06066528 |
| Sanofi | Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 Asset: Eliglustat GZ385660 | Gaucher's Disease Type I +1 | Due Dec 2026 | Q4 2025 2025-12-12 | Completed · awaiting
Updated 8mo ago
| NCT03485677 |
| Boehringer Ingelheim | Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma Asset: Brigimadlin | Liposarcoma, Dedifferentiated | Due Dec 2026 | Q4 2025 2025-12-12 | Completed · awaiting
Updated 8mo ago
| NCT06058793 |
| Apellis Pharmaceuticals, Inc. | Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe Asset: APL-2, Pegcetacoplan | Geographic Atrophy Secondary to Age-related Macular Degeneration | Due Dec 2026 | Q4 2025 2025-12-12 | Completed · awaiting
Updated 9mo ago
| NCT07214740 |
| Colgate Palmolive | Clinical Study to Evaluate the Anti-cavity Efficacy of Three Dentifrices: An In Situ Model Asset: Fluoride free toothpaste in a chalk base | Demineralization +3 | Due Dec 2026 | Q4 2025 2025-12-11 | Completed · awaiting
Updated 7mo ago
| NCT07134231 |
| Eli Lilly and Company | A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine Asset: Galcanezumab | Chronic Migraine | Due Dec 2026 | Q4 2025 2025-12-10 | Completed · awaiting
Updated 7mo ago
| NCT04616326 |
| Rose Research Center, LLC | Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders Asset: Nicoderm | Smoking Cessation +1 | Due Dec 2026 | Q4 2025 2025-12-09 | Completed · awaiting
Updated 7mo ago
| NCT06554873 |
| GlaxoSmithKline | A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old) Asset: rMenB+OMV NZ vaccine | Meningitis | Due Dec 2026 | Q4 2025 2025-12-08 | Completed · awaiting
Updated 5mo ago
| NCT06995430 |
| Novo Nordisk A/S | A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight Asset: Cagrilintide | Obesity | Due Dec 2026 | Q4 2025 2025-12-08 | Completed · awaiting
Updated 7mo ago
| NCT06131437 |
| AbbVie | A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants | Facial Volume Deficit | Due Dec 2026 | Q4 2025 2025-12-05 | Completed · awaiting
Updated 9mo ago
| NCT05818709 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease Asset: Survodutide | Obesity | Due Dec 2026 | Q4 2025 2025-12-03 | Completed · awaiting
Updated 9mo ago
| NCT06176365 |
| Immunome, Inc. | A Study of AL102 in Patients With Progressing Desmoid Tumors Asset: AL102 | Desmoid +1 | Due Dec 2026 | Q4 2025 2025-12-03 | Completed · awaiting
Updated 7mo ago
| NCT04871282 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Obesity | Due Dec 2026 | Q4 2025 2025-12-02 | Completed · awaiting
Updated 6mo ago
| NCT06066515 |
| BeiGene | Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer Asset: Pamiparib capsule | Ovarian Cancer | Due Dec 2026 | Q4 2025 2025-12-01 | Completed · awaiting
Updated 6mo ago
| NCT03519230 |
| AbbVie | Open-label Trial in Parkinson's Disease (PD) Asset: Tavapadon | Parkinson Disease | Due Dec 2026 | Q4 2025 2025-12-01 | Completed · awaiting
Updated 9mo ago
| NCT04760769 |
| Apellis Pharmaceuticals, Inc. | Pegcetacoplan Long Term Safety and Efficacy Extension Study Asset: Pegcetacoplan | PNH | Due Nov 2026 | Q4 2025 2025-11-29 | Completed · awaiting
Updated 5mo ago
| NCT03531255 |
| GB002, Inc. | Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) Asset: Placebo | Pulmonary Arterial Hypertension | Due Nov 2026 | Q4 2025 2025-11-27 | Completed · awaiting
Updated 5mo ago
| NCT05934526 |
| Vincentage Pharma Co., Ltd | A Research Study of VCT220 in Adult Chinese Participants With Obesity Asset: VCT220 | Obesity +1 | Due Nov 2026 | Q4 2025 2025-11-25 | Completed · awaiting
Updated 6mo ago
| NCT06939296 |
| Sanofi | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) Asset: Amlitelimab | Dermatitis Atopic | Due Nov 2026 | Q4 2025 2025-11-25 | Completed · awaiting
Updated 6mo ago
| NCT06181435 |
| Hutchmed | HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Asset: HMPL-523(300mg PO QD) | Warm Antibody Autoimmune Hemolytic Anemia | Due Nov 2026 | Q4 2025 2025-11-25 | Completed · awaiting
Updated 6mo ago
| NCT05535933 |
| Bristol-Myers Squibb | A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy Asset: Mavacamten | Cardiomyopathy, Hypertrophic | Due Nov 2026 | Q4 2025 2025-11-25 | Completed · awaiting
Updated 9mo ago
| NCT06253221 |
| AbbVie | A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence Asset: BOTOX | Masseter Muscle Prominence | Due Nov 2026 | Q4 2025 2025-11-25 | Completed · awaiting
Updated 9mo ago
| NCT06387394 |
| AstraZeneca | A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Asset: Baxdrostat | Uncontrolled Hypertension +1 | Due Nov 2026 | Q4 2025 2025-11-24 | Completed · awaiting
Updated 5mo ago
| NCT06344104 |
| AstraZeneca | Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China Asset: Nirsevimab | Lower Respiratory Tract Infection | Due Nov 2026 | Q4 2025 2025-11-24 | Completed · awaiting
Updated 6mo ago
| NCT05110261 |
| Colgate Palmolive | Efficacy of a Toothpaste Containing Hydrogen Peroxide as Compared to a Regular Fluoride Toothpaste Without Hydrogen Peroxide in the Immediate Removal of Tooth Stains After a Single Brushing. Asset: Optic White Adv Sparkling White (2%HP) Toothpaste | Whitening | Due Nov 2026 | Q4 2025 2025-11-24 | Completed · awaiting
Updated 9mo ago
| NCT07276672 |
| Insmed Incorporated | Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex Asset: ALIS | Mycobacterium Infections, Nontuberculous | Due Nov 2026 | Q4 2025 2025-11-21 | Completed · awaiting
Updated 8mo ago
| NCT04677569 |
| CSL Behring | Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks Asset: CSL312 | Hereditary Angioedema | Due Nov 2026 | Q4 2025 2025-11-21 | Completed · awaiting
Updated 8mo ago
| NCT04739059 |
| Eli Lilly and Company | A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) Asset: Orforglipron | Obesity +1 | Due Nov 2026 | Q4 2025 2025-11-21 | Completed · awaiting
Updated 9mo ago
| NCT06584916 |
| Hoffmann-La Roche | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Asset: Satralizumab | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) | Due Nov 2026 | Q4 2025 2025-11-20 | Completed · awaiting
Updated 5mo ago
| NCT05271409 |
| Cutia Therapeutics（Wuxi）Co.,Ltd | A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101) Asset: CU-20101 treatment for Moderate to Severe Glabellar Striae | Glabellar Frown Lines | Due Nov 2026 | Q4 2025 2025-11-20 | Completed · awaiting
Updated 8mo ago
| NCT06585696 |
| Amgen | A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis Asset: Apremilast | Plaque Psoriasis | Due Nov 2026 | Q4 2025 2025-11-20 | Completed · awaiting
Updated 9mo ago
| NCT05565560 |
| AbbVie | A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants Asset: BOTOX | Masseter Muscle Prominence | Due Nov 2026 | Q4 2025 2025-11-20 | Completed · awaiting
Updated 9mo ago
| NCT06068855 |
| CSL Behring | CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema Asset: CSL312 | Hereditary Angioedema (HAE) | Due Nov 2026 | Q4 2025 2025-11-19 | Completed · awaiting
Updated 8mo ago
| NCT05819775 |
| Novo Nordisk A/S | A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Asset: Cagrilintide | Type 2 Diabetes Mellitus | Due Nov 2026 | Q4 2025 2025-11-19 | Completed · awaiting
Updated 8mo ago
| NCT06065540 |
| Amgen | Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine Asset: Erenumab Dose 1 | Migraine | Due Nov 2026 | Q4 2025 2025-11-19 | Completed · awaiting
Updated 9mo ago
| NCT03836040 |
| Eli Lilly and Company | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Asset: Ixekizumab | Psoriatic Arthritis +1 | Due Nov 2026 | Q4 2025 2025-11-18 | Completed · awaiting
Updated 8mo ago
| NCT06588296 |
| Vifor Fresenius Medical Care Renal… | Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects Asset: Patiromer Powder for Oral Suspension (Part A) | Hyperkalemia +1 | Due Nov 2026 | Q4 2025 2025-11-18 | Completed · awaiting
Updated 5mo ago
| NCT05136664 |
| F2G Biotech GmbH | Olorofim Aspergillus Infection Study Asset: Olorofim | Invasive Aspergillosis | Due Nov 2026 | Q4 2025 2025-11-18 | Completed · awaiting
Updated 8mo ago
| NCT05101187 |
| Janssen Research & Development, LLC | A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis Asset: JNJ-77242113 | Plaque Psoriasis | Due Nov 2026 | Q4 2025 2025-11-17 | Completed · awaiting
Updated 5mo ago
| NCT06934226 |
| ModernaTX, Inc. | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ���50 Years of Age Asset: mRNA-1083 | COVID-19 +1 | Due Nov 2026 | Q4 2025 2025-11-17 | Completed · awaiting
Updated 10mo ago
| NCT06694389 |
| Sanofi Pasteur, a Sanofi Company | Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa Asset: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine | Meningococcal Immunisation +1 | Due Nov 2026 | Q4 2025 2025-11-15 | Completed · awaiting
Updated 8mo ago
| NCT05794230 |
| Eli Lilly and Company | A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine Asset: Galcanezumab | Episodic Migraine | Due Nov 2026 | Q4 2025 2025-11-14 | Completed · awaiting
Updated 8mo ago
| NCT03432286 |
| Eli Lilly and Company | A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee Asset: Retatrutide | Obesity +2 | Due Nov 2026 | Q4 2025 2025-11-14 | Completed · awaiting
Updated 8mo ago
| NCT05931367 |
| Sanofi | Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) Asset: Tolebrutinib | Primary Progressive Multiple Sclerosis | Due Nov 2026 | Q4 2025 2025-11-14 | Completed · awaiting
Updated 8mo ago
| NCT04458051 |
| Sanofi Pasteur, a Sanofi Company | Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers Asset: MenACYW conjugate vaccine | Meningococcal Immunisation +1 | Due Nov 2026 | Q4 2025 2025-11-14 | Completed · awaiting
Updated 10mo ago
| NCT06284915 |
| Zenas BioPharma (USA), LLC | A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease Asset: Obexelimab | IgG4 Related Disease | Due Nov 2026 | Q4 2025 2025-11-13 | Completed · awaiting
Updated 7mo ago
| NCT05662241 |
| Vertex Pharmaceuticals Incorporated | A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia Asset: CTX001 | Beta-Thalassemia +4 | Due Nov 2026 | Q4 2025 2025-11-13 | Completed · awaiting
Updated 9mo ago
| NCT03655678 |
| Praxis Precision Medicines | A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE) Asset: PRAX-562 | SCN2A Encephalopathy +1 | Due Nov 2026 | Q4 2025 2025-11-12 | Completed · awaiting
Updated 8mo ago
| NCT05818553 |
| Ascletis Pharmaceuticals Co., Ltd. | A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris Asset: ASC40 | Acne | Due Nov 2026 | Q4 2025 2025-11-12 | Completed · awaiting
Updated 10mo ago
| NCT06248008 |
| GlaxoSmithKline | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) Asset: Bepirovirsen | Chronic Hepatitis B +1 | Due Nov 2026 | Q4 2025 2025-11-11 | Completed · awaiting
Updated 9mo ago
| NCT05630807 |
| Boryung Pharmaceutical Co., Ltd | A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C Asset: BR1018A | Essential Hypertension +1 | Due Nov 2026 | Q4 2025 2025-11-11 | Completed · awaiting
Updated 10mo ago
| NCT06165250 |
| AbbVie | A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants Asset: BOTOX | Masseter Muscle Prominence | Due Nov 2026 | Q4 2025 2025-11-10 | Completed · awaiting
Updated 10mo ago
| NCT06399718 |
| Abcuro, Inc. | A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis Asset: ABC008 | Inclusion Body Myositis | Due Nov 2026 | Q4 2025 2025-11-06 | Completed · awaiting
Updated 8mo ago
| NCT05721573 |
| DBV Technologies | Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age Asset: DBV712 | Allergy, Peanut | Due Nov 2026 | Q4 2025 2025-11-06 | Completed · awaiting
Updated 8mo ago
| NCT05741476 |
| Haisco Pharmaceutical Group Co., L… | A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy Asset: HSK39297 tablets | PNH | Due Nov 2026 | Q4 2025 2025-11-05 | Completed · awaiting
Updated 9mo ago
| NCT06799546 |
| A. Vogel AG | Eschscholzia Study Asset: Eschscholzia tablets | Sleep | Due Nov 2026 | Q4 2025 2025-11-04 | Completed · awaiting
Updated 5mo ago
| NCT06795776 |
| Novartis Pharmaceuticals | Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS Asset: Ofatumumab | Multiple Sclerosis | Due Nov 2026 | Q4 2025 2025-11-04 | Completed · awaiting
Updated 7mo ago
| NCT04788615 |
| Colgate Palmolive | Oothpaste Containing 8% Arginine Compared to Colgate Cavity Protection Toothpaste in Reducing Dentinal Hypersensitivity Asset: Toothpaste containing 8% Arginine | Hypersensitivity | Due Nov 2026 | Q4 2025 2025-11-04 | Completed · awaiting
Updated 9mo ago
| NCT07257042 |
| AstraZeneca | Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients Asset: Acalabrutinib | Chronic Lymphocytic Leukemia | Due Nov 2026 | Q4 2025 2025-11-04 | Completed · awaiting
Updated 10mo ago
| NCT04008706 |
| GlaxoSmithKline | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) Asset: Bepirovirsen | Chronic Hepatitis B +1 | Due Nov 2026 | Q4 2025 2025-11-03 | Completed · awaiting
Updated 9mo ago
| NCT05630820 |
| RDC Clinical Pty Ltd | LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases | Healthy Volunteer +1 | Due Nov 2026 | Q4 2025 2025-11-03 | Completed · awaiting
Updated 10mo ago
| NCT06837961 |
| Immunovant Sciences GmbH | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Asset: Batoclimab | Thyroid Eye Disease | Due Nov 2026 | Q4 2025 2025-11-02 | Completed · awaiting
Updated 10mo ago
| NCT05517421 |
| Adlai Nortye Biopharma Co., Ltd. | The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC Asset: Buparlisib & Paclitaxel | Head and Neck Cancer | Due Nov 2026 | Q4 2025 2025-11-02 | Completed · awaiting
Updated 10mo ago
| NCT04338399 |
| VistaGen Therapeutics, Inc. | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) Asset: Fasedienol Nasal Spray | Social Anxiety Disorder | Due Oct 2026 | Q4 2025 2025-10-31 | Completed · awaiting
Updated 10mo ago
| NCT06358651 |
| Takeda | A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants Asset: TAK-771 | Primary Immunodeficiency Diseases (PID) | Due Oct 2026 | Q4 2025 2025-10-31 | Completed · awaiting
Updated 10mo ago
| NCT05513586 |
| Agios Pharmaceuticals, Inc. | A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) Asset: Mitapivat | Sickle Cell Disease | Due Oct 2026 | Q4 2025 2025-10-30 | Completed · awaiting
Updated 5mo ago
| NCT05031780 |
| Amgen | A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis Asset: Apremilast | Psoriasis | Due Oct 2026 | Q4 2025 2025-10-30 | Completed · awaiting
Updated 9mo ago
| NCT04175613 |
| GlaxoSmithKline | Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) Asset: Mepolizumab | Hypereosinophilic Syndrome | Due Oct 2026 | Q4 2025 2025-10-28 | Completed · awaiting
Updated 10mo ago
| NCT04965636 |
| Alume Biosciences, Inc. | Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery Asset: Bevonescein | Surgery | Due Oct 2026 | Q4 2025 2025-10-27 | Completed · awaiting
Updated 5mo ago
| NCT05377554 |
| Merck Sharp & Dohme LLC | Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) Asset: Pembrolizumab | Bladder Cancer | Due Oct 2026 | Q4 2025 2025-10-27 | Completed · awaiting
Updated 7mo ago
| NCT04700124 |
| Biohaven Pharmaceuticals, Inc. | Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder Asset: Troriluzole | Obsessive-Compulsive Disorder | Due Oct 2026 | Q4 2025 2025-10-27 | Completed · awaiting
Updated 8mo ago
| NCT04641143 |
| Gilead Sciences | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy Asset: Bictegravir | HIV-1-infection | Due Oct 2026 | Q4 2025 2025-10-27 | Completed · awaiting
Updated 10mo ago
| NCT06333808 |
| Alume Biosciences, Inc. | Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery Asset: Bevonescein | Head and Neck Surgery | Due Oct 2026 | Q4 2025 2025-10-24 | Completed · awaiting
Updated 7mo ago
| NCT06227585 |
| Ultragenyx Pharmaceutical Inc | Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Asset: Bisphosphonate | Osteogenesis Imperfecta | Due Oct 2026 | Q4 2025 2025-10-23 | Completed · awaiting
Updated 7mo ago
| NCT05768854 |
| R-Pharm | A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer Asset: RPH-051 | Locally Advanced Breast Cancer +1 | Due Oct 2026 | Q4 2025 2025-10-23 | Completed · awaiting
Updated 7mo ago
| NCT07386938 |
| Bayer | A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke Asset: Asundexian (BAY2433334) | Prevention of Ischemic Stroke +2 | Due Oct 2026 | Q4 2025 2025-10-23 | Completed · awaiting
Updated 10mo ago
| NCT05686070 |
| Astellas Pharma Inc | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause Asset: Fezolinetant | Hot Flashes | Due Oct 2026 | Q4 2025 2025-10-22 | Completed · awaiting
Updated 9mo ago
| NCT06206408 |
| Daewon Pharmaceutical Co., Ltd. | Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A Asset: DW5421A | Primary Hypercholesterolemia +1 | Due Oct 2026 | Q4 2025 2025-10-21 | Completed · awaiting
Updated 7mo ago
| NCT07444762 |
| Ultragenyx Pharmaceutical Inc | Setrusumab vs Placebo for Osteogenesis Imperfecta Asset: Setrusumab | Osteogenesis Imperfecta | Due Oct 2026 | Q4 2025 2025-10-20 | Completed · awaiting
Updated 7mo ago
| NCT05125809 |
| Corxel Pharmaceuticals | An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM Asset: Aficamten | Obstructive Hypertrophic Cardiomyopathy | Due Oct 2026 | Q4 2025 2025-10-20 | Completed · awaiting
Updated 8mo ago
| NCT06116968 |
| AbbVie | A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine Asset: Atogepant 60 mg | Episodic Migraine +1 | Due Oct 2026 | Q4 2025 2025-10-20 | Completed · awaiting
Updated 9mo ago
| NCT04686136 |
| ModernaTX, Inc. | A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age Asset: mRNA-1273.214 | SARS-CoV-2 | Due Oct 2026 | Q4 2025 2025-10-20 | Completed · awaiting
Updated 10mo ago
| NCT05436834 |
| Teikoku Seiyaku Co., Ltd. | Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains. Asset: Esflurbiprofen Topical System (EFTS) | Ankle Sprains | Due Oct 2026 | Q4 2025 2025-10-18 | Completed · awaiting
Updated 10mo ago
| NCT06866613 |
| Pharvaris Netherlands B.V. | Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Asset: Deucrictibant, Placebo | Hereditary Angioedema +13 | Due Oct 2026 | Q4 2025 2025-10-17 | Completed · awaiting
Updated 10mo ago
| NCT06343779 |
| Merck Sharp & Dohme LLC | A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) Asset: DOR/ISL | HIV Infection | Due Oct 2026 | Q4 2025 2025-10-16 | Completed · awaiting
Updated 9mo ago
| NCT05766501 |
| Novo Nordisk A/S | A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight Asset: Semaglutide | Obesity | Due Oct 2026 | Q4 2025 2025-10-15 | Completed · awaiting
Updated 5mo ago
| NCT05726227 |
| Takeda | A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Asset: TAK-279 | Generalized Pustular Psoriasis +1 | Due Oct 2026 | Q4 2025 2025-10-15 | Completed · awaiting
Updated 10mo ago
| NCT06323356 |
| Colgate Palmolive | To Assess the Efficacy of a Toothpaste Containing 8% Arginine as Compared to Colgate Cavity Protection Toothpaste in the Reduction of Dentinal Hypersensitivity. Asset: Colgate Cavity protection toothpaste | Sensitivity, Tooth | Due Oct 2026 | Q4 2025 2025-10-14 | Completed · awaiting
Updated 10mo ago
| NCT07149376 |
| Merck Sharp & Dohme LLC | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Asset: Pembrolizumab | Triple Negative Breast Neoplasms | Due Oct 2026 | Q4 2025 2025-10-14 | Completed · awaiting
Updated 11mo ago
| NCT03036488 |
| Genmab | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China Asset: Epcoritamab | Diffuse Large B-Cell Lymphoma | Due Oct 2026 | Q4 2025 2025-10-13 | Completed · awaiting
Updated 5mo ago
| NCT07226752 |
| Genmab | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Asset: Epcoritamab | Diffuse Large B-cell Lymphoma | Due Oct 2026 | Q4 2025 2025-10-13 | Completed · awaiting
Updated 5mo ago
| NCT04628494 |
| Janssen Research & Development, LLC | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Asset: Teclistamab | Relapsed or Refractory Multiple Myeloma | Due Oct 2026 | Q4 2025 2025-10-13 | Completed · awaiting
Updated 5mo ago
| NCT05572515 |
| Taisho Pharmaceutical Co., Ltd. | A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis Asset: TS-172 20~60 mg/day | Hyperphosphatemia Patients on Hemodialysis | Due Oct 2026 | Q4 2025 2025-10-13 | Completed · awaiting
Updated 10mo ago
| NCT06745531 |
| Astellas Pharma Global Development… | A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease Asset: pudexacianinium chloride | Intraoperative Ureter Visualization +1 | Due Oct 2026 | Q4 2025 2025-10-13 | Completed · awaiting
Updated 10mo ago
| NCT05999747 |
| Merck Sharp & Dohme LLC | DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) Asset: DOR/ISL | HIV-1 Infection | Due Oct 2026 | Q4 2025 2025-10-13 | Completed · awaiting
Updated 11mo ago
| NCT05705349 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) | Obesity +1 | Due Oct 2026 | Q4 2025 2025-10-09 | Completed · awaiting
Updated 6mo ago
| NCT06309992 |
| Hoffmann-La Roche | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Asset: Crovalimab | Atypical Hemolytic Uremic Syndrome | Due Oct 2026 | Q4 2025 2025-10-09 | Completed · awaiting
Updated 5mo ago
| NCT04861259 |
| Actelion | Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Asset: Macitentan 10 mg | Pulmonary Arterial Hypertension | Due Oct 2026 | Q4 2025 2025-10-07 | Completed · awaiting
Updated 5mo ago
| NCT04273945 |
| Teva Pharmaceuticals USA | Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis Asset: Tapinarof Cream 1% | Plaque Type Psorisis | Due Oct 2026 | Q4 2025 2025-10-07 | Completed · awaiting
Updated 9mo ago
| NCT06742957 |
| AstraZeneca | A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy Asset: Ceralasertib | Advanced or Metastatic Non-Small Cell Lung Cancer | Due Oct 2026 | Q4 2025 2025-10-06 | Completed · awaiting
Updated 5mo ago
| NCT05450692 |
| AbbVie | Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder Asset: Cariprazine Flexible Dose | Schizophrenia +2 | Due Oct 2026 | Q4 2025 2025-10-06 | Completed · awaiting
Updated 11mo ago
| NCT04578756 |
| Dexa Medica Group | The Efficacy and Safety of Reconyl in Acute Cough Treatment Asset: Reconyl | Cough | Due Oct 2026 | Q4 2025 2025-10-03 | Completed · awaiting
Updated 7mo ago
| NCT07420491 |
| Daewoong Pharmaceutical Co. LTD. | Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension Asset: DWC202404, DWC202314 | Hypertension +1 | Due Oct 2026 | Q4 2025 2025-10-02 | Completed · awaiting
Updated 7mo ago
| NCT06682000 |
| AstraZeneca | Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) Asset: Durvalumab | Biliary Tract Cancer | Due Oct 2026 | Q4 2025 2025-10-02 | Completed · awaiting
Updated 5mo ago
| NCT05771480 |
| Servier | Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation Asset: Vorasidenib | Residual or Recurrent Grade 2 IDH Mutant Glioma | Due Oct 2026 | Q4 2025 2025-10-02 | Completed · awaiting
Updated 8mo ago
| NCT06780930 |
| Sanofi | Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 Asset: Venglustat | Gaucher's Disease Type III | Due Oct 2026 | Q4 2025 2025-10-02 | Completed · awaiting
Updated 11mo ago
| NCT05222906 |
| Novo Nordisk A/S | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise Asset: Cagrilintide | Type 2 Diabetes | Due Oct 2026 | Q4 2025 2025-10-01 | Completed · awaiting
Updated 6mo ago
| NCT06323174 |
| Dexa Medica Group | DLBS2411 Treatment For Functional Dyspepsia Asset: Placebo caplet of DLBS2411 | Functional Dyspepsia | Due Oct 2026 | Q4 2025 2025-10-01 | Completed · awaiting
Updated 7mo ago
| NCT05248802 |
| Hoffmann-La Roche | A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) | Non-Small-Cell Lung | Due Oct 2026 | Q4 2025 2025-10-01 | Completed · awaiting
Updated 8mo ago
| NCT03456063 |
| Harmony Biosciences Management, Inc. | A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia Asset: Pitolisant | Idiopathic Hypersomnia +1 | Due Oct 2026 | Q4 2025 2025-10-01 | Completed · awaiting
Updated 9mo ago
| NCT05458128 |
| Bristol-Myers Squibb | A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants Asset: Luspatercept | Myelodysplastic Syndromes | Due Oct 2026 | Q4 2025 2025-10-01 | Completed · awaiting
Updated 10mo ago
| NCT06045689 |
| Q3 2025 · 18 | ||||||
| Cogent Biosciences, Inc. | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors Asset: CGT9486 | Advanced Gastrointestinal Stromal Tumors +1 | Due Sep 2026 | Q3 2025 2025-09-30 | Completed · awaiting
Updated 7mo ago
| NCT05208047 |
| Pfizer | A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults Asset: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE | Respiratory Syncytial Virus (RSV) | Due Sep 2026 | Q3 2025 2025-09-30 | Completed · awaiting
Updated 10mo ago
| NCT06890416 |
| Celgene | To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis Asset: Ozanimod | Colitis, Ulcerative | Due Sep 2026 | Q3 2025 2025-09-30 | Completed · awaiting
Updated 11mo ago
| NCT03915769 |
| R-Pharm | A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma Asset: RPH-002 | Head and Neck Squamous Cell Carcinoma | Due Sep 2026 | Q3 2025 2025-09-29 | Completed · awaiting
Updated 7mo ago
| NCT07435324 |
| Shanghai Hengrui Pharmaceutical Co… | The Trial of SHR6508 in Secondary Hyperparathyroidism Asset: SHR6508 plus oral placebo tablets | Secondary Hyperparathyroidism | Due Sep 2026 | Q3 2025 2025-09-29 | Completed · awaiting
Updated 9mo ago
| NCT06434961 |
| Achieve Life Sciences | Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers Asset: Cytisinicline | Smoking Cessation +1 | Due Sep 2026 | Q3 2025 2025-09-29 | Completed · awaiting
Updated 10mo ago
| NCT06435221 |
| Gilead Sciences | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen Asset: Bictegravir | HIV-1-infection | Due Sep 2026 | Q3 2025 2025-09-29 | Completed · awaiting
Updated 11mo ago
| NCT05502341 |
| Sunshine Guojian Pharmaceutical (S… | Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis Asset: 611 | Dermatitis, Atopic | Due Sep 2026 | Q3 2025 2025-09-26 | Completed · awaiting
Updated 8mo ago
| NCT06173284 |
| Laboratorios Silanes S.A. de C.V. | Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm Asset: Etoricoxib + Tizanidine fixed dose | Acute Low-back Pain +1 | Due Sep 2026 | Q3 2025 2025-09-26 | Completed · awaiting
Updated 8mo ago
| NCT06863662 |
| Eli Lilly and Company | A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin Asset: Orforglipron | Type 2 Diabetes | Due Sep 2026 | Q3 2025 2025-09-26 | Completed · awaiting
Updated 11mo ago
| NCT06192108 |
| Otsuka Pharmaceutical Development … | A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder Asset: SEP-363856 | Generalized Anxiety Disorder | Due Sep 2026 | Q3 2025 2025-09-26 | Completed · awaiting
Updated 11mo ago
| NCT05729373 |
| Cali Pharmaceuticals LLC | CPL-01 in the Management of Postoperative Pain After Bunionectomy Asset: Local anesthetic injection of CPL-01 | Bunion +1 | Due Sep 2026 | Q3 2025 2025-09-25 | Completed · awaiting
Updated 6mo ago
| NCT05831449 |
| Eli Lilly and Company | A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis Asset: Placebo | Atopic Dermatitis | Due Sep 2026 | Q3 2025 2025-09-25 | Completed · awaiting
Updated 11mo ago
| NCT06280716 |
| Alumis Inc | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 Asset: Envudeucitinib | Plaque Psoriasis | Due Sep 2026 | Q3 2025 2025-09-23 | Completed · awaiting
Updated 5mo ago
| NCT06588738 |
| Nxera Pharma Korea Co., Ltd. | A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder Asset: Daridorexant | Insomnia Disorder | Due Sep 2026 | Q3 2025 2025-09-23 | Completed · awaiting
Updated 8mo ago
| NCT07028697 |
| AbbVie | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo Asset: Upadacitinib | Vitiligo | Due Sep 2026 | Q3 2025 2025-09-23 | Completed · awaiting
Updated 10mo ago
| NCT06118411 |
| Teikoku Seiyaku Co., Ltd. | Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions Asset: Esflurbiprofen Topical System (EFTS) | Contusions | Due Sep 2026 | Q3 2025 2025-09-22 | Completed · awaiting
Updated 11mo ago
| NCT06871046 |
| Pfizer | A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan Asset: 20-valent pneumococcal conjugate vaccine | Pneumococcal Disease | Due Sep 2026 | Q3 2025 2025-09-20 | Completed · awaiting
Updated 9mo ago
| NCT05512819 |
Upcoming readouts — next 12 months
· 300Industry Phase 3 trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Hangzhou Zhongmei Huadong Pharmace… | Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes Asset: HDM1005 1 | Obesity & Overweight | Recruiting | Q3 2026 2026-09-20 (est.) | Estimated · aging
Updated 9mo ago
| NCT07279194 |
| Karuna Therapeutics, Inc., a Brist… | A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) Asset: KarXT | Alzheimer Disease | Recruiting | Q3 2026 2026-09-21 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06585787 |
| Cardiol Therapeutics Inc. | CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) Asset: CardiolRx | Recurrent Pericarditis | Recruiting | Q3 2026 2026-09-21 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06708299 |
| Biogen | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus Asset: Litifilimab | Lupus Erythematosus, Systemic | Active Not Recruiting | Q3 2026 2026-09-27 (est.) | Estimated · aging
Updated 8mo ago
| NCT04961567 |
| Ocugen | A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease Asset: OCU410ST | Stargardt Disease | Active Not Recruiting | Q3 2026 2026-09-28 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05956626 |
| Amgen | A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State Asset: Dazodalibep | Sjögren's Syndrome (SS) | Active Not Recruiting | Q4 2026 2026-10-22 (est.) | Estimated · aging
Updated 8mo ago
| NCT06245408 |
| Novartis Pharmaceuticals | Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) Asset: Ianalumab | Primary Immune Thrombocytopenia (ITP) | Active Not Recruiting | Q4 2026 2026-10-29 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05653349 |
| Sanofi | Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis Asset: Frexalimab | Multiple Sclerosis | Active Not Recruiting | Q4 2026 2026-12-23 (est.) | Estimated · aging
Updated 7mo ago
| NCT06141486 |
Unlock 292 more readouts · filter by sponsor, indication, and time window
From the briefs
All briefs →Plain-English deep dives on the mechanisms, targets and trials behind these readouts.
How to Read a Cancer Trial and Tell If Patients Live Longer
A cancer drug 'works.' But did patients live longer, or did a tumor just shrink? The answer is which endpoint the trial made its primary measure. Here is how to read it.
The Daraxonrasib Success Story
How RAS went from "undruggable" to Rasonque, the first RAS-targeted medicine to extend survival in pancreatic cancer, and the best reporting and science behind it.
Can an IBD Biologic Last Six Months?
Several companies want to stretch IBD antibodies from a shot every few weeks to one every three months, or even six. Keeping the drug in the blood that long is the easy part. Whether the disease stays controlled right up to the next dose is the hard part, and the bet the newest programs are making.
Does Blocking IL-17F Actually Matter?
Two of the newest PsA drugs block IL-17F as well as IL-17A; the older ones block only IL-17A. A plain walk through what the extra target actually buys: clear help on the skin, no proven help on the joints yet, and a fungal cost in the middle.
Fifteen Drugs by Blocking. None by Switching On.
The TNF receptor superfamily has produced fifteen approved medicines, and every one of them works by shutting something down. Six receptors have been pushed the other way for twenty years, and not one agonist antibody has been approved.
The Disease That Wasn't Rare After All
The scan that finds it is quick, safe, and has been around for years. Almost no cardiologist used it until a drug gave them a reason to look.
Methodology & caveats
Why this is harder than it looks
There is no single “readout date” on any public registry. A Phase 3 trial generates three different dated events, only one of which is registered:
- Primary completion date — last patient finishes the primary endpoint analysis. This is the only event published on ClinicalTrials.gov.
- Topline announcement — the company press release / 8-K that actually moves the stock. Typically lands 3–9 months after primary completion. Not registered anywhere structured.
- Results posted to CT.gov — full data uploaded to the registry. Mandated by FDAAA within 12 months of primary completion (often hits the deadline).
Most sponsor-supplied dates are ESTIMATED and can slip silently. Plenty of "active" trials haven't been touched on CT.gov in 12+ months — the date you see may be a stale ghost.
How we label every row
We anchor on CT.gov primary completion (the only public, structured signal) and combine date type (ACTUAL vs ESTIMATED) with the time since the sponsor last updated the trial record:
- Read out — results have been posted to ClinicalTrials.gov (definitive).
- Completed · awaiting — primary completion is ACTUAL but no results yet (topline often already announced; sponsor has 12 months under FDAAA to post).
- Estimated · fresh / aging / stale — sponsor estimate, with last-update freshness in 3 buckets (≤6 mo / 6–12 mo / >12 mo).
What we explicitly don't claim
We do not predict topline announcement dates and we do not score per-trial slip risk. Both would require SEC EDGAR full-text NCT linking and historical version snapshots — separate enrichments we've scoped but not built. Other free retail calendars conflate ACTUAL/ESTIMATED dates and don't flag staleness; we label them so you don't have to guess which dates are credible.
Coverage
Source: ClinicalTrials.gov v2 API. We list industry-sponsored Phase 3 trials with primary completion in the last 6 months or next 12+ months. Excluded: TERMINATED, WITHDRAWN, SUSPENDED. Phase 2 readouts are out of scope today (5x volume, separate sprint).